- Published on
Medicine – Causes of Proteinuria
Proteinuria means an abnormal amount of protein in the urine. It may be temporary and benign, or it may indicate significant renal disease. The causes are most usefully understood according to whether the proteinuria is transient, glomerular, tubular, overflow, or post-renal.
1. Infection and Febrile Illness
The original notes correctly include:
Fever.
Acute febrile illness can cause:
Transient proteinuria.
This usually resolves once the acute illness settles.
Therefore, a small amount of protein detected during fever does not automatically indicate chronic kidney disease.
2. Urinary Tract Infection
A UTI can produce mild proteinuria because inflammation within the urinary tract allows protein and inflammatory material to enter the urine.
It is often associated with:
Pyuria.
Bacteriuria.
Dysuria.
Frequency.
Proteinuria from uncomplicated UTI is usually:
Mild rather than nephrotic-range.
3. Chronic Pyelonephritis
Chronic pyelonephritis and chronic tubulointerstitial scarring can cause:
Persistent low-grade proteinuria.
Because the main pathology affects:
Tubules and interstitium,
the amount of protein is usually less than in major glomerular disease.
4. Renal Tuberculosis
Genitourinary tuberculosis can cause:
Proteinuria.
However, its more characteristic urinary finding is:
Persistent sterile pyuria.
Microscopic haematuria may also occur.
Therefore:
RENAL TB → THINK STERILE PYURIA MORE THAN HEAVY PROTEINURIA.
5. Glomerular Disease
Glomerular disease is the major cause of:
Moderate to heavy proteinuria.
Damage to the glomerular filtration barrier allows excessive plasma proteins, especially:
Albumin,
to enter the urine.
6. Diabetes Mellitus
The original notes correctly include:
Diabetes mellitus.
Diabetic kidney disease causes:
Glomerular hyperfiltration.
GBM thickening.
Mesangial expansion.
Intraglomerular hypertension.
These changes lead to increasing urinary albumin loss.
7. Proteinuria in Diabetic Kidney Disease
The traditional sequence is:
Normal albumin excretion
↓
Moderately increased albuminuria
↓
Severely increased albuminuria
↓
Heavy proteinuria
↓
Progressive CKD.
However, some patients can develop declining GFR without marked albuminuria.
8. Hypertension
Long-standing hypertension can cause:
Hypertensive nephrosclerosis.
This may produce:
Persistent proteinuria.
Usually the amount is:
Low to moderate.
If proteinuria is very heavy, another glomerular cause should be considered.
9. Pre-Eclampsia
The original notes include:
Pre-eclampsia.
Pre-eclampsia occurs after approximately:
20 weeks of pregnancy
and causes:
Hypertension with maternal organ dysfunction.
Proteinuria is common.
10. Mechanism in Pre-Eclampsia
The renal lesion classically involves:
Glomerular endotheliosis.
This increases glomerular permeability and produces:
Proteinuria.
In severe disease, proteinuria may become:
Nephrotic-range.
11. Acute Glomerulonephritis
Acute GN may cause:
Proteinuria.
However, the classic nephritic pattern also includes:
Haematuria.
Dysmorphic RBCs.
RBC casts.
Hypertension.
Reduced GFR.
Proteinuria is usually less marked than in nephrotic syndrome, though overlap can occur.
12. Chronic Glomerulonephritis
Chronic GN may cause:
Persistent proteinuria
with gradual progression to:
Chronic kidney disease.
The quantity depends on the underlying glomerular lesion.
13. Nephrotic Syndrome
The original notes list:
Nephrotic syndrome.
This is not a single disease, but a clinical syndrome characterised by:
Heavy proteinuria.
Hypoalbuminaemia.
Generalised oedema.
Hyperlipidaemia.
14. Common Causes of Nephrotic-Range Proteinuria
Important causes include:
Minimal change disease.
FSGS.
Membranous nephropathy.
Diabetic kidney disease.
Amyloidosis.
Membranous lupus nephritis.
15. Neoplastic Causes
The original notes include:
Renal tract tumour
and
Multiple myeloma.
These cause proteinuria through very different mechanisms.
16. Renal Tract Tumour
Tumours of the kidney or urinary tract may cause protein to appear in urine because of:
Bleeding.
Inflammation.
Parenchymal disruption.
However, the more characteristic finding is:
Haematuria.
Marked isolated proteinuria is not usually the main presentation.
17. Multiple Myeloma
Multiple myeloma can produce:
Overflow proteinuria.
This occurs because large quantities of monoclonal:
Free light chains
are produced and filtered by the kidney.
18. Bence Jones Protein
The older term:
Bence Jones protein
refers to urinary monoclonal free light chains.
Modern assessment commonly uses:
Serum free light chains.
Serum immunofixation.
Urine studies when indicated.
19. Important Dipstick Limitation in Myeloma
Standard urine dipsticks detect mainly:
Albumin.
Therefore a patient with large amounts of:
Light-chain proteinuria
may have substantial total urinary protein despite only modest dipstick positivity.
This is an important clue to:
Paraprotein-related kidney disease.
20. Acute Tubular Injury
The original notes include:
ATN, more accurately often termed:
Acute tubular injury – ATI.
Tubular injury can cause:
Tubular proteinuria.
21. Mechanism of Tubular Proteinuria
Normally, small low-molecular-weight proteins are filtered and then reabsorbed by:
Proximal tubular cells.
When tubular function is damaged, reabsorption falls.
Therefore these proteins remain in the urine.
22. Amount of Protein in Tubular Disease
Tubular proteinuria is usually:
Mild to moderate.
It is generally less severe than:
Glomerular proteinuria.
Therefore nephrotic-range proteinuria should usually suggest:
A glomerular process.
23. Acute Interstitial Nephritis
Acute interstitial nephritis can cause:
Mild-to-moderate proteinuria.
It is often associated with:
Sterile pyuria.
WBC casts.
Microscopic haematuria.
AKI.
24. NSAID-Associated AIN
An important exception is:
NSAID-related acute interstitial nephritis.
This can occasionally cause:
Heavy or nephrotic-range proteinuria,
especially when associated with:
Minimal-change-like glomerular injury.
25. Transient Proteinuria
An important category missing from the original list is:
Transient proteinuria.
Possible causes include:
Fever.
Strenuous exercise.
Acute illness.
Seizures.
Severe physiological stress.
It usually resolves when the trigger disappears.
26. Orthostatic Proteinuria
Another important benign cause is:
Orthostatic proteinuria.
This occurs mainly in:
Adolescents and young adults.
Protein appears when the patient is upright but falls or disappears during:
Overnight recumbency.
27. Orthostatic Pattern
A typical pattern is:
Daytime urine → protein present.
First-morning urine → normal or minimal protein.
This is generally benign.
28. Glomerular Proteinuria
Glomerular proteinuria occurs when the filtration barrier becomes abnormally permeable.
The dominant urinary protein is usually:
Albumin.
Important causes include:
Diabetes.
Primary GN.
Secondary GN.
Nephrotic syndromes.
Pre-eclampsia.
29. Tubular Proteinuria
Tubular proteinuria results from impaired proximal tubular reabsorption.
Causes include:
Acute tubular injury.
Acute interstitial nephritis.
Chronic tubulointerstitial disease.
30. Overflow Proteinuria
Overflow proteinuria occurs when excessive amounts of small proteins circulate in plasma and overwhelm tubular reabsorption.
The classic cause is:
Multiple myeloma.
Other examples include:
Myoglobin in rhabdomyolysis.
Haemoglobin in intravascular haemolysis.
31. Post-Renal Proteinuria
Protein can also enter urine from inflammation or bleeding after it has left the glomerulus.
This is called:
Post-renal proteinuria.
Examples include:
UTI.
Urinary tract inflammation.
Tumours.
Bleeding.
This usually produces relatively modest proteinuria.
32. Proteinuria and Amyloidosis
An important cause not listed originally is:
Amyloidosis.
Amyloid deposition in the glomeruli can cause:
Heavy proteinuria
and
Nephrotic syndrome.
This is particularly important in:
AL amyloidosis
and
AA amyloidosis.
33. Proteinuria and SLE
Systemic lupus erythematosus can cause:
Lupus nephritis.
Proteinuria may occur in several lupus nephritis classes.
A particularly strong nephrotic association is:
Class V membranous lupus nephritis.
34. Measuring Proteinuria
Modern assessment usually uses a spot urine:
Albumin:creatinine ratio – ACR
for albuminuria.
A:
Protein:creatinine ratio – PCR
may be useful when total protein is more relevant.
35. ACR Categories
Albuminuria is commonly classified as:
A1 – normal to mildly increased.
A2 – moderately increased.
A3 – severely increased.
Interpretation should always be combined with:
eGFR
and
clinical context.
36. Confirm Persistent Proteinuria
A single positive urine result does not necessarily indicate chronic kidney disease.
Proteinuria may be transient because of:
Fever.
Exercise.
UTI.
Acute illness.
Therefore persistent proteinuria usually requires:
Repeat testing.
37. First-Morning Urine
A:
First-morning urine sample
is useful because it reduces the effects of:
Posture.
Exercise.
Daytime activity.
It is especially useful when considering:
Orthostatic proteinuria.
38. Proteinuria with Haematuria
The combination:
Proteinuria + haematuria
raises concern for:
Glomerular disease.
This is particularly important when associated with:
Dysmorphic RBCs.
RBC casts.
Reduced renal function.
Hypertension.
39. Proteinuria with Oedema
Heavy urinary protein loss causes:
Hypoalbuminaemia.
This lowers plasma oncotic pressure and contributes to:
Generalised oedema.
Therefore:
HEAVY PROTEINURIA + HYPOALBUMINAEMIA + OEDEMA → THINK NEPHROTIC SYNDROME.
40. Proteinuria with Diabetes
In diabetes, persistent albuminuria may indicate:
Diabetic kidney disease.
However, consider another diagnosis if there is:
Rapid renal deterioration.
Active urine sediment.
Marked haematuria.
Abrupt heavy proteinuria.
41. Proteinuria with Myeloma Features
Think of myeloma when proteinuria occurs with:
Anaemia.
Bone pain.
Hypercalcaemia.
Renal dysfunction.
Monoclonal protein abnormalities.
42. Infection Causes – Note Form
Fever:
Transient proteinuria.
Usually resolves when illness settles.
UTI:
Usually mild post-renal proteinuria.
Often accompanied by pyuria and bacteriuria.
Chronic pyelonephritis:
Usually low-grade proteinuria from tubulointerstitial scarring.
Renal TB:
Can cause proteinuria, but sterile pyuria is more characteristic.
43. Glomerular Causes – Note Form
Diabetes:
Major cause of persistent albuminuria.
May progress to nephrotic-range proteinuria.
Hypertension:
Usually low-to-moderate proteinuria.
Very heavy proteinuria suggests another glomerular disorder.
Pre-eclampsia:
Proteinuria due to glomerular endotheliosis.
Acute and chronic GN:
Proteinuria often with haematuria and RBC casts.
Nephrotic syndrome:
Heavy proteinuria with hypoalbuminaemia and oedema.
44. Neoplastic Causes – Note Form
Renal tract tumour:
Can cause proteinuria through bleeding or local tissue injury.
Haematuria is more characteristic.
Multiple myeloma:
Overflow proteinuria due to monoclonal free light chains.
45. Tubular Causes – Note Form
Acute tubular injury:
Impaired reabsorption of low-molecular-weight proteins.
Usually mild-to-moderate proteinuria.
Acute interstitial nephritis:
Mild-to-moderate proteinuria.
Often with sterile pyuria and WBC casts.
46. Important Additions
Other important causes include:
Orthostatic proteinuria.
Exercise-induced transient proteinuria.
Amyloidosis.
Lupus nephritis.
Minimal change disease.
FSGS.
Membranous nephropathy.
Rhabdomyolysis-related myoglobinuria.
47. Important Corrections to the Original Notes
Nephrotic syndrome is not itself a single disease.
It is a:
CLINICAL SYNDROME CAUSED BY UNDERLYING GLOMERULAR DISORDERS.
Hypertension generally causes:
LOW-TO-MODERATE PROTEINURIA.
Marked nephrotic-range proteinuria should prompt consideration of:
ANOTHER GLOMERULAR DISEASE.
Renal tract tumours more classically cause:
HAEMATURIA
than heavy proteinuria.
Renal TB is more classically associated with:
STERILE PYURIA.
ATN/ATI and interstitial nephritis usually cause:
TUBULAR, GENERALLY NON-NEPHROTIC PROTEINURIA.
Key Clinical Pattern
Think of proteinuria by mechanism:
GLOMERULAR → ALBUMIN LEAK.
Examples:
DIABETES + GN + NEPHROTIC DISEASE + PRE-ECLAMPSIA.
TUBULAR → FAILURE TO REABSORB SMALL PROTEINS.
Examples:
ATI/ATN + INTERSTITIAL NEPHRITIS.
OVERFLOW → TOO MUCH SMALL PROTEIN IN THE BLOOD.
Classic example:
MYELOMA LIGHT CHAINS.
POST-RENAL → PROTEIN ENTERS URINE FROM THE URINARY TRACT.
Examples:
UTI + TUMOUR + BLEEDING.
And remember:
HEAVY PROTEINURIA + OEDEMA + HYPOALBUMINAEMIA → NEPHROTIC SYNDROME.
PROTEINURIA + HAEMATURIA + RBC CASTS → THINK GLOMERULONEPHRITIS.
- Published on
Medicine – Causes of Acute Kidney Injury
Acute kidney injury (AKI) is the modern term that has largely replaced acute renal failure (ARF). It refers to an abrupt reduction in kidney function, usually detected by a rise in serum creatinine and/or a fall in urine output.
The causes are classically divided into:
Pre-renal AKI – reduced renal perfusion.
Intrinsic renal AKI – structural injury within the kidney.
Post-renal AKI – obstruction to urine flow.
Historically, more than 90% of cases were said to result from pre-renal causes or acute tubular necrosis, but this should be regarded as older teaching rather than a fixed modern percentage because the distribution varies with the patient population and clinical setting.
1. Pre-Renal AKI
Pre-renal AKI occurs when the kidneys receive insufficient blood flow but the renal parenchyma is initially structurally intact.
The kidney responds appropriately to poor perfusion by retaining:
Sodium.
Water.
This produces:
Low-volume, concentrated urine.
If renal perfusion is restored early, renal function can recover rapidly.
2. Hypovolaemia
A major cause of pre-renal AKI is:
Reduced circulating volume.
Causes include:
Vomiting.
Diarrhoea.
Haemorrhage.
Burns.
Poor fluid intake.
Excessive fluid losses.
These reduce renal perfusion and therefore lower:
GFR.
3. Haemorrhage
Major blood loss reduces:
Effective circulating volume.
Examples include:
Gastrointestinal bleeding.
Trauma.
Surgical bleeding.
Obstetric haemorrhage.
If severe or prolonged, pre-renal hypoperfusion can progress to:
Acute tubular injury.
4. Sepsis
Sepsis is an important cause of AKI.
It may cause:
Systemic vasodilatation.
Relative hypovolaemia.
Abnormal renal microcirculation.
Inflammatory tubular injury.
Therefore septic AKI may contain both:
Pre-renal and intrinsic renal components.
5. Heart Failure
Severe cardiac failure can reduce:
Effective renal blood flow.
Even when the patient is fluid overloaded, renal perfusion may still be poor.
This can produce:
Cardiorenal AKI.
6. Cirrhosis
Advanced cirrhosis causes marked:
Splanchnic vasodilatation.
This reduces effective arterial circulating volume and renal perfusion.
Severe cases may develop:
Hepatorenal syndrome.
7. ACE Inhibitors and ARBs
The original notes correctly include:
ACE inhibitors.
ACE inhibitors and ARBs dilate the:
Efferent arteriole.
This reduces intraglomerular pressure.
They can precipitate AKI particularly when renal filtration is dependent on angiotensin II, for example in:
Severe volume depletion.
Bilateral renal artery stenosis.
Stenosis of a solitary functioning kidney.
8. NSAIDs and Renal Perfusion
NSAIDs can also contribute to haemodynamic AKI.
They inhibit prostaglandin synthesis, causing:
Afferent arteriolar vasoconstriction.
Therefore:
NSAID → reduced renal blood flow → reduced GFR.
The risk is greater in:
Volume depletion.
Heart failure.
CKD.
Older patients.
9. Intrinsic Renal AKI
Intrinsic renal AKI occurs when there is structural injury involving:
Tubules.
Glomeruli.
Interstitial tissue.
Renal blood vessels.
The most common intrinsic cause is:
Acute tubular injury, traditionally called acute tubular necrosis – ATN.
10. Acute Tubular Necrosis / Acute Tubular Injury
ATN is commonly caused by:
Ischaemia
or
Nephrotoxicity.
The modern term:
Acute tubular injury – ATI
is often more accurate because widespread true tubular necrosis is not always present.
11. Ischaemic ATN
Ischaemic ATN may occur after:
Hypovolaemia.
Severe haemorrhage.
Shock.
Sepsis.
Cardiovascular collapse.
Major surgery.
The typical progression is:
Hypoperfusion → pre-renal AKI → prolonged ischaemia → tubular injury.
12. Nephrotoxic ATN
Nephrotoxins can directly damage renal tubular epithelial cells.
Examples include:
Aminoglycosides.
Some chemotherapy drugs.
Radiographic contrast in susceptible patients.
Myoglobin from rhabdomyolysis.
Haemoglobin from severe intravascular haemolysis.
Various toxins.
13. Multifactorial ATN
The original notes correctly state that ATN is often:
Multifactorial.
A critically ill patient may simultaneously have:
Sepsis.
Hypotension.
Volume depletion.
Nephrotoxic drug exposure.
Therefore more than one mechanism may contribute to AKI.
14. Renal Vascular Causes
Renal vascular disease may cause AKI through obstruction or injury to:
Large vessels
or
Small renal vessels.
15. Renal Artery Thrombosis or Embolism
Acute occlusion of a renal artery may cause:
Renal infarction.
Possible features include:
Sudden flank pain.
Haematuria.
Raised LDH.
AKI is particularly likely when the lesion is:
Bilateral
or affects a:
Solitary functioning kidney.
16. Renal Artery Stenosis
Chronic renal artery stenosis more commonly causes:
Hypertension
than sudden AKI.
However, severe bilateral stenosis can cause AKI, particularly after:
ACE inhibitor or ARB treatment.
17. Hypertensive Emergency
The older term:
Accelerated hypertension
is now often replaced by:
Hypertensive emergency.
Severe hypertension can cause:
Endothelial injury.
Fibrinoid necrosis.
Hyperplastic arteriolosclerosis.
Renal ischaemia.
This may lead to:
AKI.
18. Scleroderma Renal Crisis
Systemic sclerosis can cause:
Scleroderma renal crisis.
Typical features include:
Abrupt severe hypertension.
Rapidly rising creatinine.
Microangiopathic haemolytic anaemia.
Treatment requires prompt:
ACE inhibitor therapy, usually with captopril initially.
19. Pre-Eclampsia
Pre-eclampsia can cause renal dysfunction through:
Endothelial injury
and
Glomerular endotheliosis.
Features include:
Hypertension.
Proteinuria.
Reduced renal function.
Severe disease may be associated with:
HELLP syndrome.
20. Glomerulonephritis
Glomerulonephritis can cause:
Nephritic AKI.
Typical urinary findings include:
Haematuria.
Proteinuria.
Dysmorphic RBCs.
RBC casts.
Patients may also develop:
Hypertension.
Oedema.
Reduced GFR.
21. IgA Nephropathy
IgA nephropathy may cause acute deterioration in renal function, particularly in severe disease.
The classic clinical pattern is:
Visible haematuria occurring during or shortly after an upper respiratory infection.
This is called:
Synpharyngitic haematuria.
22. Mesangiocapillary GN
The older term:
Mesangiocapillary GN
corresponds broadly to:
Membranoproliferative glomerulonephritis – MPGN.
Modern classification separates:
Immune-complex-mediated disease
from
Complement-mediated disease such as C3 glomerulopathy.
23. Post-Infectious Glomerulonephritis
Post-infectious GN may follow:
Streptococcal infection.
Typical features include:
Cola-coloured urine.
Haematuria.
Oedema.
Hypertension.
AKI.
Low C3.
24. Infective Endocarditis
Infective endocarditis can cause:
Immune-complex glomerulonephritis.
Possible findings include:
Fever.
Heart murmur.
Haematuria.
Proteinuria.
Low complement.
AKI.
25. Other Infection-Related GN
Persistent infections such as:
Deep abscesses
may occasionally produce:
Immune-complex glomerular injury.
These are less common but remain recognised causes.
26. Acute Interstitial Nephritis
Acute interstitial nephritis affects:
Renal interstitium and tubules.
The most common cause is:
Drug-induced immune injury.
27. Drugs Causing AIN
Important examples include:
Penicillins and other beta-lactam antibiotics.
Rifampicin.
Sulfonamides.
NSAIDs.
Proton-pump inhibitors.
Thiazide diuretics.
Furosemide.
28. Clinical Features of AIN
AIN may produce:
AKI.
Sterile pyuria.
WBC casts.
Mild proteinuria.
Microscopic haematuria.
Some patients develop:
Fever.
Rash.
Eosinophilia.
However, the classic triad is present in only a minority.
29. Pyelonephritis
Severe pyelonephritis can cause AKI, especially when there is:
Sepsis.
Bilateral disease.
Obstruction.
Pre-existing renal impairment.
Uncomplicated unilateral pyelonephritis usually does not cause severe renal failure.
30. Legionella Infection
Legionella can be associated with AKI through:
Sepsis.
Rhabdomyolysis.
Tubulointerstitial injury.
Therefore its renal effects may be multifactorial.
31. Epstein–Barr Virus
EBV can rarely cause:
Tubulointerstitial nephritis.
This is much less common than drug-induced AIN.
32. Leptospirosis
Leptospirosis may cause:
Tubulointerstitial renal injury
and severe systemic disease.
Possible associated findings include:
Jaundice.
Thrombocytopenia.
AKI.
Severe leptospirosis is sometimes termed:
Weil disease.
33. Vasculitic and Rapidly Progressive Renal Disease
Systemic vasculitides can cause:
Necrotising glomerulonephritis
and rapidly progressive AKI.
These conditions usually require urgent:
ANCA testing.
Other immunological investigations.
Kidney biopsy.
34. Anti-GBM Disease
The older notes place:
Goodpasture syndrome
under vasculitis.
Strictly, anti-GBM disease is not a classic systemic vasculitis.
It causes:
Rapidly progressive crescentic GN
and may also cause:
Pulmonary alveolar haemorrhage.
Typical renal biopsy immunofluorescence shows:
Linear IgG along the GBM.
35. Granulomatosis with Polyangiitis
The old term:
Wegener’s granulomatosis
is now:
Granulomatosis with polyangiitis – GPA.
Features may include:
ENT disease.
Pulmonary nodules or haemorrhage.
Rapidly progressive GN.
It is commonly associated with:
PR3-ANCA.
36. Microscopic Polyangiitis
Microscopic polyangiitis – MPA commonly causes:
Pauci-immune necrotising glomerulonephritis.
It may also produce:
Pulmonary haemorrhage.
It is often associated with:
MPO-ANCA.
37. Eosinophilic Granulomatosis with Polyangiitis
The old term:
Churg–Strauss syndrome
is now:
Eosinophilic granulomatosis with polyangiitis – EGPA.
Typical features include:
Asthma.
Eosinophilia.
Systemic vasculitis.
Renal involvement can occur.
38. IgA Vasculitis
The old term:
Henoch–Schönlein purpura
is now:
IgA vasculitis.
Typical features include:
Palpable purpura.
Arthralgia.
Abdominal pain.
Renal involvement resembling IgA nephropathy.
39. Cryoglobulinaemia
Cryoglobulinaemic disease may cause:
Immune-complex glomerulonephritis.
Possible findings include:
Purpura.
Neuropathy.
Haematuria.
Proteinuria.
Low complement, especially C4.
40. Haematological Causes
Important haematological causes of AKI include:
Multiple myeloma.
Haemolytic uraemic syndrome.
Other thrombotic microangiopathies.
41. Multiple Myeloma
The classic mechanism of AKI in myeloma is:
Light-chain cast nephropathy.
Filtered monoclonal light chains form casts within tubules and produce:
Tubular obstruction and direct toxicity.
42. Other Mechanisms in Myeloma
Myeloma may also cause kidney injury through:
Hypercalcaemia.
Dehydration.
AL amyloidosis.
Monoclonal immunoglobulin deposition disease.
Infection.
43. Haemolytic Uraemic Syndrome
HUS is a:
Thrombotic microangiopathy.
The classic triad is:
Microangiopathic haemolytic anaemia.
Thrombocytopenia.
AKI.
44. Thrombotic Microangiopathy
A patient with:
AKI + thrombocytopenia + haemolytic anaemia + schistocytes
should raise suspicion for:
TMA.
This includes:
HUS.
TTP.
Complement-mediated TMA.
45. Rhabdomyolysis
Rhabdomyolysis causes:
Massive skeletal muscle breakdown.
This releases:
Myoglobin.
Myoglobin can cause:
Pigment-associated acute tubular injury.
Typical clues include:
Markedly raised CK.
Dark urine.
Hyperkalaemia.
46. Hepatorenal Syndrome
The original notes place hepatorenal syndrome among intrinsic renal causes, but it is better understood as:
Functional renal failure caused by severe circulatory disturbance in advanced liver disease.
The kidney may initially be structurally normal.
Therefore it is more closely related to:
Pre-renal physiology.
47. Systemic Lupus Erythematosus
SLE may cause AKI through:
Lupus nephritis.
Severe proliferative lupus nephritis can cause:
Haematuria.
Proteinuria.
RBC casts.
Rapidly declining GFR.
Typical immunological clues include:
Raised anti-dsDNA.
Low C3 and C4.
48. Acute Pancreatitis
Severe pancreatitis may cause AKI through:
Hypovolaemia.
Third-space fluid losses.
Systemic inflammation.
Sepsis.
Shock.
Therefore the renal injury is often:
Pre-renal initially, followed by tubular injury if severe or prolonged.
49. Hypercalcaemia
Severe hypercalcaemia can cause AKI through:
Renal vasoconstriction.
Nephrogenic diabetes insipidus.
Volume depletion.
Tubular injury.
Therefore:
HYPERCALCAEMIA → POLYURIA + DEHYDRATION + REDUCED RENAL PERFUSION → AKI.
50. Acute Urate Nephropathy
Large quantities of uric acid can precipitate within renal tubules.
This causes:
Tubular obstruction
and
AKI.
The classic setting is:
Tumour lysis syndrome.
51. Tumour Lysis Syndrome
Tumour lysis syndrome produces:
Hyperuricaemia.
Hyperkalaemia.
Hyperphosphataemia.
Hypocalcaemia.
These abnormalities can cause severe:
AKI and cardiac arrhythmias.
52. Post-Renal AKI
Post-renal AKI occurs when:
Urinary outflow is obstructed.
For significant AKI to develop, obstruction usually needs to be:
Bilateral
or involve a:
Solitary functioning kidney.
53. Renal and Ureteric Stones
Renal stones can cause post-renal AKI when there is:
Bilateral ureteric obstruction
or obstruction of a:
Single functioning kidney.
A unilateral stone in a patient with two normal kidneys usually does not cause major AKI.
54. Benign Prostatic Enlargement
In older men, an important cause is:
Benign prostatic enlargement.
This may cause:
Bladder outlet obstruction.
Urinary retention.
Hydronephrosis.
Post-renal AKI.
55. Malignant Obstruction
Malignancy may obstruct the urinary tract.
Examples include:
Prostate cancer.
Bladder cancer.
Pelvic malignancies.
Retroperitoneal tumours.
These may produce:
Bilateral ureteric obstruction.
56. Retroperitoneal Fibrosis
Retroperitoneal fibrosis may surround and compress:
Both ureters.
This can lead to:
Hydronephrosis
and
Post-renal AKI.
57. Papillary Necrosis
Papillary necrosis is primarily an:
Intrinsic renal papillary lesion.
However, sloughed papillae can obstruct the ureter and cause:
Post-renal obstruction.
Therefore it may contribute to post-renal AKI in selected cases.
58. Causes of Papillary Necrosis
Classic associations include:
Diabetes mellitus.
Analgesic nephropathy.
Sickle-cell disease or trait.
Severe pyelonephritis.
Detached papillae may then:
Obstruct urine flow.
59. Other Post-Renal Causes
Important additional causes include:
Neurogenic bladder.
Urethral stricture.
Blood clots.
Bladder tumours.
Pelvic masses.
60. Pre-Renal Causes – Note Form
Hypovolaemia:
Vomiting.
Diarrhoea.
Haemorrhage.
Burns.
Poor fluid intake.
Reduced effective circulating volume:
Heart failure.
Cirrhosis.
Sepsis.
Drug-related haemodynamic AKI:
ACE inhibitors.
ARBs.
NSAIDs.
61. Intrinsic Renal Causes – Note Form
Acute tubular injury:
Prolonged hypoperfusion.
Haemorrhage.
Shock.
Sepsis.
Nephrotoxins.
Rhabdomyolysis.
Vascular:
Renal artery thrombosis or embolism.
Severe bilateral renal artery stenosis.
Hypertensive emergency.
Scleroderma renal crisis.
Pre-eclampsia.
Thrombotic microangiopathy.
Glomerular:
IgA nephropathy.
MPGN pattern.
Post-infectious GN.
Endocarditis-associated GN.
Lupus nephritis.
ANCA-associated GN.
Anti-GBM disease.
Cryoglobulinaemic GN.
Interstitial:
Drug-induced AIN.
Severe pyelonephritis.
Leptospirosis.
Rare viral-associated interstitial nephritis.
Haematological:
Myeloma.
HUS and other TMA.
Other intrinsic or mixed causes:
Rhabdomyolysis.
Hypercalcaemia.
Urate nephropathy.
Severe pancreatitis-related AKI.
62. Post-Renal Causes – Note Form
Stones:
Bilateral ureteric stones.
Stone in a solitary functioning kidney.
Prostatic obstruction:
Benign prostatic enlargement.
Prostate cancer.
Malignant obstruction:
Bladder cancer.
Pelvic malignancy.
Retroperitoneal tumour.
Other obstruction:
Retroperitoneal fibrosis.
Neurogenic bladder.
Urethral stricture.
Blood clot.
Sloughed renal papilla.
63. Important Corrections to the Original Notes
ARF should generally be replaced with:
AKI – ACUTE KIDNEY INJURY.
The statement:
“More than 90% are pre-renal or ATN”
is best regarded as:
Historical teaching rather than a universal modern figure.
Goodpasture syndrome is better classified as:
ANTI-GBM DISEASE
rather than a conventional systemic vasculitis.
Wegener’s granulomatosis is now:
GRANULOMATOSIS WITH POLYANGIITIS – GPA.
Churg–Strauss syndrome is now:
EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS – EGPA.
Henoch–Schönlein purpura is now:
IgA VASCULITIS.
Hepatorenal syndrome is primarily a:
FUNCTIONAL HAEMODYNAMIC RENAL FAILURE
rather than intrinsic tubular damage.
Pancreatitis usually causes AKI through:
HYPOVOLAEMIA + SYSTEMIC INFLAMMATION + SHOCK.
Papillary necrosis is an intrinsic renal lesion, but:
SLOUGHED PAPILLAE MAY SECONDARILY CAUSE POST-RENAL OBSTRUCTION.
64. Practical Diagnostic Approach
When AKI is detected, first ask:
Is the kidney underperfused?
If yes:
Think pre-renal.
Then ask:
Is there urinary obstruction?
Check for:
Urinary retention.
Hydronephrosis.
Prostatic disease.
Stones.
If yes:
Think post-renal.
If neither clearly explains the AKI, investigate:
Intrinsic renal disease.
Important clues include:
RBC casts → glomerulonephritis.
WBC casts → AIN or pyelonephritis.
Muddy brown casts → acute tubular injury.
Heavy proteinuria → glomerular disease.
Anaemia + thrombocytopenia + schistocytes → TMA.
High CK → rhabdomyolysis.
Key Clinical Pattern
Remember:
PRE-RENAL = PERFUSION PROBLEM.
Examples:
HYPOVOLAEMIA + SEPSIS + HEART FAILURE + CIRRHOSIS + HAEMODYNAMIC DRUG EFFECTS.
INTRINSIC RENAL = KIDNEY TISSUE DAMAGE.
Examples:
ATN/ATI + GN + AIN + VASCULAR DISEASE + MYELOMA + TMA + RHABDOMYOLYSIS.
POST-RENAL = OBSTRUCTION.
Examples:
PROSTATE + STONES + MALIGNANCY + RETROPERITONEAL FIBROSIS + NEUROGENIC BLADDER.
The simplest examination framework is:
LOW PERFUSION → PRE-RENAL.
ACTIVE URINE SEDIMENT → INTRINSIC RENAL.
ANURIA / RETENTION / HYDRONEPHROSIS → POST-RENAL.
- Published on
Medicine – Acute Tubular Necrosis
Acute tubular necrosis (ATN) is a common cause of intrinsic acute kidney injury (AKI) caused by injury to renal tubular epithelial cells. The term is still widely used, although acute tubular injury (ATI) is often more accurate because histological necrosis is not always present.
ATN most commonly results from either ischaemia due to prolonged renal hypoperfusion or direct nephrotoxic injury. It is often reversible if the underlying cause is corrected and the patient survives the acute illness.
1. Basic Mechanism
The kidney normally receives a large proportion of cardiac output.
When renal blood flow falls significantly and remains reduced for long enough, tubular epithelial cells become:
Ischaemic.
This leads to:
Tubular cell injury.
Cell detachment.
Tubular obstruction.
Back-leak of filtrate.
Reduced GFR.
The result is:
Intrinsic AKI due to acute tubular injury.
2. Ischaemic ATN
The original notes correctly identify:
Renal hypoperfusion
as an important cause.
Examples include:
Severe hypovolaemia.
Major haemorrhage.
Septic shock.
Cardiogenic shock.
Prolonged hypotension.
Major surgery.
3. Progression from Pre-Renal AKI to ATN
Pre-renal AKI begins with:
Reduced renal perfusion but structurally intact tubules.
If hypoperfusion is corrected early, renal function may return rapidly.
However, if reduced perfusion is prolonged:
Pre-renal AKI → tubular ischaemia → acute tubular injury/ATN.
At this point, simply restoring circulating volume may no longer produce an immediate recovery in renal function.
4. Sepsis and ATN
Sepsis is a particularly important cause of AKI.
The mechanism is more complex than simple low blood pressure.
Sepsis can cause:
Abnormal renal microcirculation.
Inflammation.
Endothelial dysfunction.
Tubular cellular injury.
Therefore septic AKI may occur even without profound sustained hypotension.
5. Nephrotoxic ATN
An important cause not included in the original notes is:
Nephrotoxic tubular injury.
Examples include:
Aminoglycosides.
Certain chemotherapy drugs.
Radiographic contrast in susceptible patients.
Myoglobin in rhabdomyolysis.
Haemoglobin in severe intravascular haemolysis.
Some toxins.
6. Rhabdomyolysis
In rhabdomyolysis:
Skeletal muscle breakdown → myoglobin release → tubular toxicity and obstruction.
This can cause:
Pigment-associated acute tubular injury.
Therefore rhabdomyolysis is an important cause of intrinsic AKI.
7. Histological Changes
ATN/ATI primarily affects:
Renal tubular epithelial cells.
Microscopy may show:
Tubular epithelial cell injury.
Loss of brush border.
Tubular dilation.
Cell detachment.
Granular casts.
The extent of actual necrosis can vary.
8. Why the Term ATI Is Often Preferred
The term:
Acute tubular necrosis
suggests widespread tubular cell death.
In reality, many patients have significant tubular dysfunction without extensive histological necrosis.
Therefore:
Acute tubular injury – ATI
is often the more precise pathological term.
However, ATN remains common in clinical teaching and examinations.
9. Clinical Course
ATN is often:
Potentially reversible.
Tubular epithelial cells have some ability to:
Recover and regenerate.
If the underlying cause is corrected and complications are managed, renal function may recover over:
Days to weeks.
Some severe cases take longer.
10. Dialysis During Recovery
Some patients develop severe AKI and require:
Temporary dialysis.
Dialysis supports the patient while the kidneys recover.
Indications are based on complications such as:
Refractory hyperkalaemia.
Pulmonary oedema.
Severe metabolic acidosis.
Uraemic complications.
11. Dialysis Does Not Treat the Tubular Injury Directly
Dialysis does not regenerate renal tubules.
Instead, it temporarily replaces functions such as:
Potassium removal.
Acid removal.
Fluid removal.
Clearance of uraemic solutes.
Renal recovery depends on resolution of the underlying injury and tubular repair.
12. Phases of ATN
The classical course can be divided into:
Initiation phase.
Maintenance phase.
Recovery phase.
Not every patient follows a perfectly defined sequence.
13. Initiation Phase
During the initiation phase, the kidney is exposed to:
Ischaemia or nephrotoxins.
Renal function begins to decline.
Early correction of the underlying cause may limit the severity of tubular damage.
14. Maintenance Phase
During the maintenance phase, GFR remains reduced.
Patients may develop:
Oliguria
or sometimes:
Non-oliguric AKI.
Complications include:
Hyperkalaemia.
Acidosis.
Fluid overload.
Uraemia.
15. Recovery Phase
During recovery, tubular function begins to improve and GFR rises.
Some patients enter a:
Diuretic phase
with increased urine output.
This occurs because filtration may improve before tubular concentrating and reabsorptive capacity has fully recovered.
16. Diuretic Recovery Phase
During the recovery phase, patients may pass:
Large volumes of relatively dilute urine.
This can cause losses of:
Water.
Sodium.
Potassium.
Therefore recovery still requires careful monitoring.
17. Oliguric and Non-Oliguric ATN
ATN does not always cause very low urine output.
It may be:
Oliguric
or
Non-oliguric.
Therefore:
Normal or high urine volume does not exclude ATN.
This supports the original point that ATN can produce either low- or relatively high-volume urine.
18. Initial Treatment
The original notes state:
“Initial treatment requires aggressive fluid resuscitation.”
This needs an important correction.
Fluids should be given when there is:
True hypovolaemia or haemodynamic volume depletion.
They should not be given aggressively to every patient with ATN regardless of volume status.
19. Why Excessive Fluids Can Be Harmful
Once ATN is established, the kidney may be unable to excrete excess fluid.
Over-resuscitation can therefore cause:
Peripheral oedema.
Pulmonary oedema.
Worsening oxygenation.
Therefore:
Correct hypovolaemia, but avoid indiscriminate ongoing fluid loading.
20. Fluid Challenge
When pre-renal hypovolaemia is suspected, a carefully assessed fluid challenge may help determine whether renal perfusion improves.
If the problem is purely pre-renal, correction of hypovolaemia may lead to:
Improved urine output
and
Improvement in renal function.
However, response to fluids must be interpreted clinically and is not an absolute diagnostic test.
21. ATN after Fluid Resuscitation
In established ATN:
Urine output may remain low despite restoration of adequate circulating volume.
This reflects intrinsic tubular damage rather than persistent simple hypovolaemia.
The key point is:
Do not continue giving large amounts of fluid solely because urine output remains low.
22. Distinguishing Pre-Renal AKI from ATN
The original notes emphasise an important clinical distinction.
In pre-renal AKI, the tubules remain functionally intact and try to conserve:
Sodium and water.
Therefore urine tends to be:
Low volume
and
Concentrated.
23. Urine in Pre-Renal AKI
Because functioning tubules conserve water, the urine is often:
Concentrated.
This reflects an appropriate renal response to reduced circulating volume.
Urine sodium may also be relatively:
Low
in classic pre-renal states.
24. Urine in ATN
In ATN, damaged tubules lose some ability to:
Reabsorb sodium
and
Concentrate urine.
Therefore urine may be relatively:
Dilute
and contain more sodium.
The old description of:
“Poor-quality urine”
essentially refers to urine that is poorly concentrated because tubular function is impaired.
25. Urine Microscopy in ATN
A particularly useful finding is:
Muddy brown granular casts.
These are strongly suggestive of:
Acute tubular injury.
Renal tubular epithelial cells may also be seen.
26. Urine Microscopy in Pre-Renal AKI
In uncomplicated pre-renal AKI, the urine sediment is usually:
Bland
or relatively unremarkable.
Therefore:
Muddy brown casts → favour ATN.
Bland sediment → more consistent with pre-renal AKI, although not diagnostic by itself.
27. Fractional Excretion of Sodium
A traditional test used to distinguish pre-renal AKI from ATN is:
Fractional excretion of sodium – FeNa.
It estimates the percentage of filtered sodium that is excreted in urine.
28. Typical FeNa Pattern
Classically:
FeNa <1% → suggests pre-renal AKI.
FeNa >2% → suggests ATN.
However, these are teaching patterns rather than absolute rules.
29. Limitations of FeNa
FeNa can be misleading in:
Diuretic use.
Sepsis.
Early ATN.
Chronic kidney disease.
Pigment nephropathy.
Some forms of glomerulonephritis.
Therefore FeNa should never be interpreted in isolation.
30. Fractional Excretion of Urea
When patients are receiving diuretics, some clinicians use:
Fractional excretion of urea – FeUrea.
A low value may support pre-renal physiology.
However, FeUrea also has important limitations and is not perfectly diagnostic.
31. Urine Osmolality
In classic pre-renal AKI:
Urine osmolality tends to be higher
because intact tubules conserve water.
In ATN:
Urine osmolality tends to be lower
because concentrating ability is impaired.
Again, there is overlap between the two conditions.
32. Response to Fluids
The original notes correctly state that pre-renal AKI often improves relatively quickly when the underlying hypovolaemia is corrected.
Therefore:
Pre-renal AKI → restoration of perfusion → urine output and renal function may improve.
In ATN:
Renal dysfunction persists despite restoration of adequate perfusion.
33. Important Limitation of the Fluid-Response Test
Not every patient with pre-renal AKI immediately produces a dramatic diuresis after fluids.
Likewise, some patients with ATN may improve gradually.
Therefore:
Response to fluids is supportive, not an absolute diagnostic rule.
34. Management of ATN
The main principles are:
Treat the underlying cause.
Optimise haemodynamics.
Avoid further nephrotoxins.
Manage fluid balance carefully.
Monitor electrolytes and acid-base status.
Treat complications.
35. Treat the Underlying Cause
Examples include:
Treat sepsis promptly.
Control haemorrhage.
Correct true hypovolaemia.
Stop nephrotoxic drugs where possible.
Treat rhabdomyolysis.
Relieve obstruction if present.
36. Avoid Further Nephrotoxins
Further renal injury should be minimised.
Important considerations include avoiding or carefully reviewing:
NSAIDs.
Aminoglycosides.
Other nephrotoxic medications.
Drug doses should also be adjusted for reduced renal function.
37. Monitor Fluid Balance
Close monitoring includes:
Urine output.
Daily weight.
Fluid intake and output.
Blood pressure.
Peripheral oedema.
Signs of pulmonary oedema.
38. Monitor Blood Tests
Important repeated blood tests include:
Creatinine.
Urea.
Potassium.
Bicarbonate.
Calcium.
Phosphate.
The frequency depends on the severity of illness.
39. Hyperkalaemia
ATN can cause reduced potassium excretion and therefore:
Hyperkalaemia.
Severe hyperkalaemia may require urgent treatment and, if refractory:
Dialysis.
40. Metabolic Acidosis
Failure to excrete acid can lead to:
Metabolic acidosis.
Severe refractory acidosis can become an indication for:
Urgent kidney replacement therapy.
41. Fluid Overload
Because damaged kidneys may not excrete sodium and water effectively, patients may develop:
Fluid overload.
This may progress to:
Pulmonary oedema.
Refractory pulmonary oedema is an important indication for dialysis.
42. Nutrition
Patients with severe AKI are often catabolic.
Adequate nutritional support is important, while avoiding:
Excessive potassium.
Excessive phosphate.
Unnecessary fluid load
when these are clinically problematic.
43. Diuretics
Loop diuretics may be used to manage:
Fluid overload
when the patient is responsive.
However, diuretics do not reliably:
Reverse tubular injury
or
Accelerate renal recovery.
They should not be used simply to convert oliguric ATN into non-oliguric ATN.
44. Prognosis
ATN is often reversible, particularly when:
The underlying cause is corrected early.
The patient avoids further nephrotoxic injury.
Severe complications are treated appropriately.
However, recovery is not always complete.
45. Long-Term Outcome
Some patients recover to their previous baseline kidney function.
Others may be left with:
Residual CKD.
Severe AKI also increases the future risk of:
Progressive chronic kidney disease.
Therefore renal function should be reassessed after recovery.
46. Pre-Renal AKI – Note Form
Mechanism:
Reduced renal perfusion.
Tubules initially structurally intact.
Urine volume:
Usually low.
Urine concentration:
Usually concentrated.
Urine sediment:
Usually bland.
Urine sodium:
Often low.
FeNa:
Classically <1%.
Response to fluids:
Often improves if true hypovolaemia is corrected.
47. ATN – Note Form
Mechanism:
Ischaemic or nephrotoxic tubular injury.
Urine volume:
May be low or relatively preserved/high.
Urine concentration:
Often relatively dilute because tubular concentrating ability is impaired.
Urine sediment:
Muddy brown granular casts.
Renal tubular epithelial cells.
Urine sodium:
Often higher than in classic pre-renal AKI.
FeNa:
Classically >2%, but not always.
Response to fluids:
Renal dysfunction persists despite restoration of adequate perfusion.
48. Important Corrections to the Original Notes
The term:
“Acute tubular necrosis”
is still widely used, but:
ACUTE TUBULAR INJURY – ATI
is often more pathologically accurate.
The original notes focus only on:
Ischaemic injury.
ATN can also be caused by:
NEPHROTOXINS.
The statement:
“Initial treatment requires aggressive fluid resuscitation”
should be corrected to:
GIVE APPROPRIATE IV FLUIDS WHEN TRUE HYPOVOLAEMIA IS PRESENT.
Once circulation is restored:
DO NOT CONTINUE AGGRESSIVE FLUID LOADING JUST BECAUSE URINE OUTPUT REMAINS LOW.
The original phrase:
“Poor-quality urine”
means that damaged tubules are unable to concentrate urine normally.
A better description is:
RELATIVELY DILUTE URINE DUE TO IMPAIRED TUBULAR REABSORPTION AND CONCENTRATING ABILITY.
The distinction between pre-renal AKI and ATN is useful, but no single test is perfect.
Diagnosis should combine:
History + volume assessment + urine microscopy + laboratory findings + response to correction of the cause.
49. High-Yield Pathway
The classical progression is:
HYPOVOLAEMIA / SHOCK / SEPSIS
↓
REDUCED RENAL PERFUSION
↓
Initially:
PRE-RENAL AKI
↓
If prolonged:
TUBULAR ISCHAEMIA
↓
ACUTE TUBULAR INJURY / ATN
↓
MUDDY BROWN CASTS + IMPAIRED CONCENTRATION + PERSISTENT AKI
↓
If recovery occurs:
TUBULAR REGENERATION
↓
DIURETIC RECOVERY PHASE
↓
RENAL FUNCTION IMPROVES
Key Clinical Pattern
Think:
PRE-RENAL = TUBULES STILL WORK.
Therefore the kidney tries to conserve:
SALT + WATER → LOW-VOLUME, CONCENTRATED URINE.
ATN = TUBULES ARE DAMAGED.
Therefore they cannot conserve sodium and water normally:
RELATIVELY DILUTE URINE + MUDDY BROWN GRANULAR CASTS.
The most useful practical distinction is:
PRE-RENAL AKI → IMPROVES WHEN RENAL PERFUSION IS RESTORED.
ESTABLISHED ATN → AKI PERSISTS DESPITE CORRECTION OF HYPOVOLAEMIA.
And remember:
FLUIDS TREAT HYPOVOLAEMIA — NOT LOW URINE OUTPUT BY ITSELF.
- Published on
Medicine – Severe Complications of Acute Kidney Injury
Acute kidney injury (AKI) is the modern term that has largely replaced acute renal failure (ARF). Severe AKI can rapidly produce life-threatening disturbances in electrolytes, acid–base balance, fluid status and uraemic toxin accumulation.
The most important complications to recognise urgently are hyperkalaemia, pulmonary oedema, severe volume disturbance, metabolic acidosis and uraemic complications such as bleeding, encephalopathy and pericarditis.
1. Hyperkalaemia
Hyperkalaemia is one of the most immediately dangerous complications of AKI.
When renal function falls, the kidneys are less able to excrete:
Potassium.
As a result, serum potassium may rise rapidly.
2. Why Hyperkalaemia Is Dangerous
Severe hyperkalaemia can disturb cardiac electrical activity and cause:
Tall peaked T waves.
PR prolongation.
Loss of P waves.
QRS widening.
Sine-wave pattern.
Ventricular arrhythmias.
Cardiac arrest.
Therefore:
AKI + severe hyperkalaemia = medical emergency.
3. Factors That Can Worsen Hyperkalaemia
Hyperkalaemia may become more severe when AKI is associated with:
Metabolic acidosis.
Tissue breakdown.
Rhabdomyolysis.
Haemolysis.
Certain medications.
Important drugs include:
ACE inhibitors.
ARBs.
Potassium-sparing diuretics.
4. Management of Severe Hyperkalaemia
Immediate treatment may include:
Intravenous calcium when there are significant ECG changes or severe hyperkalaemia requiring membrane stabilisation.
Insulin with glucose to shift potassium into cells.
Nebulised beta₂-agonist as an additional intracellular shift.
The underlying cause should be corrected, and potassium-removing strategies should be used as appropriate.
5. Hyperkalaemia and Dialysis
If hyperkalaemia is:
Severe.
Persistent.
Recurrent after temporary treatment.
or
Associated with dangerous ECG abnormalities,
urgent dialysis may be required.
Therefore:
REFRACTORY HYPERKALAEMIA → URGENT DIALYSIS.
6. Pulmonary Oedema
AKI can impair the renal excretion of:
Sodium
and
Water.
This can lead to rapid expansion of extracellular fluid volume.
If fluid accumulates in the lungs, the patient develops:
Pulmonary oedema.
7. Clinical Features of Pulmonary Oedema
Possible features include:
Severe breathlessness.
Orthopnoea.
Hypoxaemia.
Fine inspiratory crackles.
Raised JVP.
Peripheral oedema.
Respiratory distress.
8. Why Pulmonary Oedema Is Dangerous
Pulmonary oedema interferes with:
Oxygen transfer across the alveolar-capillary membrane.
This can cause:
Severe hypoxaemia
and potentially:
Respiratory failure.
Therefore it must be recognised and treated rapidly.
9. Management of Fluid Overload
Management may include:
Oxygen or ventilatory support when required.
Fluid restriction.
Salt restriction.
Loop diuretics if the patient is capable of responding.
If pulmonary oedema remains refractory, dialysis may be required.
10. Pulmonary Oedema and Dialysis
A major indication for urgent dialysis is:
SEVERE FLUID OVERLOAD WITH PULMONARY OEDEMA THAT CANNOT BE ADEQUATELY CONTROLLED MEDICALLY.
This corresponds to the:
“O – Overload”
in the AEIOU mnemonic for dialysis indications.
11. Intravascular Volume Depletion
The original notes correctly mention:
Intravascular volume depletion.
AKI can occur because of volume depletion, but severe AKI can also coexist with or worsen intravascular depletion depending on the underlying illness.
Possible causes include:
Vomiting.
Diarrhoea.
Haemorrhage.
Sepsis.
Burns.
Third-space fluid loss.
12. Consequences of Volume Depletion
Reduced circulating volume causes:
Reduced renal perfusion.
This may worsen:
Pre-renal AKI
and, if prolonged, may progress to:
Acute tubular injury.
13. Clinical Features of Volume Depletion
Possible findings include:
Hypotension.
Postural hypotension.
Tachycardia.
Dry mucous membranes.
Reduced peripheral perfusion.
Low urine output.
However, physical signs are imperfect and should be interpreted with the overall clinical picture.
14. Volume Replacement
When true hypovolaemia is present, treatment usually involves:
Appropriate intravenous fluid replacement.
The amount and rate depend on:
Cause.
Blood pressure.
Cardiac status.
Urine output.
Evidence of ongoing losses.
15. Fluid Overload
At the opposite extreme, AKI can also cause:
Fluid overload.
This occurs because impaired kidneys cannot adequately excrete sodium and water.
Therefore AKI can present with either:
Volume depletion
or
Volume overload.
16. Clinical Features of Fluid Overload
Features include:
Peripheral oedema.
Raised JVP.
Weight gain.
Hypertension.
Pulmonary crackles.
Pulmonary oedema.
17. Why Volume Assessment Matters
Incorrect fluid treatment can worsen AKI.
Giving excessive fluid to a patient who is already overloaded may cause:
Pulmonary oedema.
Conversely, failing to replace true volume depletion can worsen:
Renal hypoperfusion.
Therefore:
ASSESS VOLUME STATUS CAREFULLY BEFORE GIVING LARGE AMOUNTS OF FLUID.
18. Bleeding
Severe renal failure can cause a:
Bleeding tendency
because uraemia impairs:
Platelet function.
Platelet numbers may be relatively normal, but platelet adhesion and aggregation are impaired.
This is called:
Uraemic platelet dysfunction.
19. Clinical Features of Uraemic Bleeding
Possible manifestations include:
Easy bruising.
Epistaxis.
Bleeding from venepuncture sites.
Gastrointestinal bleeding.
Mucosal bleeding.
Prolonged bleeding after procedures.
20. Why Uraemic Bleeding Occurs
The main problem is not usually severe thrombocytopenia.
Instead, uraemic toxins interfere with:
Platelet adhesion.
Platelet aggregation.
Interaction between platelets and vascular endothelium.
Therefore:
Platelet count may be normal despite significant bleeding risk.
21. Management of Uraemic Bleeding
Management depends on severity.
Important measures may include:
Correcting severe uraemia.
Treating anaemia when relevant.
Avoiding unnecessary antiplatelet or anticoagulant exposure where possible.
Dialysis when bleeding is clinically significant and related to uraemia.
Other specific haemostatic measures may be used depending on the clinical setting.
22. Bleeding as a Dialysis Indication
Clinically significant:
Uraemic bleeding
is an indication for urgent dialysis.
Therefore:
URAEMIA + SIGNIFICANT BLEEDING → CONSIDER URGENT DIALYSIS.
23. Metabolic Acidosis
An important severe complication not included in the original list is:
Metabolic acidosis.
Healthy kidneys normally:
Excrete hydrogen ions
and
Regenerate bicarbonate.
AKI impairs these processes.
24. Consequences of Severe Acidosis
Severe metabolic acidosis can cause:
Reduced myocardial contractility.
Hypotension.
Reduced responsiveness to catecholamines.
Respiratory compensation with rapid breathing.
It can also worsen:
Hyperkalaemia.
25. Acidosis and Dialysis
If metabolic acidosis is:
Severe
and
Refractory to appropriate medical treatment,
particularly when causing haemodynamic compromise, dialysis may be required.
Therefore:
SEVERE REFRACTORY METABOLIC ACIDOSIS → URGENT DIALYSIS.
26. Uraemic Encephalopathy
Another important severe complication is:
Uraemic encephalopathy.
Accumulation of uraemic toxins can impair cerebral function.
27. Clinical Features of Uraemic Encephalopathy
Possible features include:
Confusion.
Poor concentration.
Drowsiness.
Asterixis.
Altered consciousness.
Seizures in severe cases.
28. Uraemic Encephalopathy and Dialysis
Uraemic encephalopathy is a major indication for:
Urgent dialysis.
Therefore:
URAEMIA + ENCEPHALOPATHY → URGENT DIALYSIS.
29. Uraemic Pericarditis
Severe uraemia can also cause:
Pericardial inflammation.
This is called:
Uraemic pericarditis.
30. Clinical Features of Uraemic Pericarditis
Possible features include:
Chest pain.
Pericardial friction rub.
Pericardial effusion.
A large effusion may progress to:
Cardiac tamponade.
31. Uraemic Pericarditis and Dialysis
Uraemic pericarditis is another strong indication for:
Urgent kidney replacement therapy.
Therefore:
URAEMIC PERICARDITIS → URGENT DIALYSIS.
32. Other Electrolyte Abnormalities
AKI may also cause abnormalities in:
Phosphate.
Calcium.
Magnesium.
Hyperphosphataemia is common as phosphate excretion falls.
Calcium may fall, particularly in advanced renal dysfunction.
These abnormalities are important, although usually less immediately dangerous than severe hyperkalaemia.
33. Hyponatraemia
Excess water retention may cause:
Dilutional hyponatraemia.
Severe or rapidly developing hyponatraemia can cause neurological symptoms, although sodium abnormalities in AKI depend greatly on fluid intake and the underlying illness.
34. Infection and Sepsis
Sepsis is a major cause of AKI and can also complicate the course.
Patients with severe AKI are often critically ill and may have:
Impaired immune function.
Invasive lines or catheters.
Prolonged hospitalisation.
These factors increase infection risk.
35. Cardiovascular Complications
AKI can stress the cardiovascular system through:
Hyperkalaemia.
Acidosis.
Fluid overload.
Hypertension or hypotension.
This can precipitate:
Arrhythmias.
Heart failure.
Pulmonary oedema.
Haemodynamic instability.
36. Neurological Complications
Severe AKI and uraemia may cause:
Confusion.
Encephalopathy.
Asterixis.
Seizures.
Neurological dysfunction should raise concern for:
Severe uraemia
and possible need for dialysis.
37. Gastrointestinal Manifestations of Uraemia
Severe uraemia can produce:
Anorexia.
Nausea.
Vomiting.
These symptoms can worsen:
Nutrition
and
Volume depletion.
Persistent severe uraemic symptoms may contribute to the decision to begin kidney replacement therapy.
38. Severe AKI Complications – Note Form
Hyperkalaemia:
Reduced renal potassium excretion.
Risk of fatal arrhythmia.
Severe/refractory cases may require dialysis.
Pulmonary oedema:
Sodium and water retention.
Breathlessness and hypoxaemia.
Refractory pulmonary oedema is an urgent dialysis indication.
Intravascular volume depletion:
Reduced circulating volume.
Reduced renal perfusion.
Can worsen pre-renal AKI and lead to tubular injury.
Volume overload:
Oedema.
Raised JVP.
Hypertension.
Pulmonary oedema.
Bleeding:
Uraemic platelet dysfunction.
Platelet count may be normal.
Clinically significant uraemic bleeding may require dialysis.
Metabolic acidosis:
Reduced renal acid excretion.
Can worsen hyperkalaemia and cardiovascular instability.
Severe refractory acidosis may require dialysis.
Uraemic encephalopathy:
Confusion.
Drowsiness.
Asterixis.
Seizures.
Urgent dialysis indication.
Uraemic pericarditis:
Chest pain.
Pericardial rub.
Effusion.
Urgent dialysis indication.
39. Important Corrections to the Original Notes
The term:
“ARF”
should now generally be replaced by:
ACUTE KIDNEY INJURY – AKI.
The original list includes:
“Intravascular volume depletion/overload.”
This is important, but these are opposite states and should be separated clinically:
VOLUME DEPLETION → REDUCED RENAL PERFUSION.
VOLUME OVERLOAD → OEDEMA/PULMONARY OEDEMA.
The original complication:
“Bleeding”
is best understood as:
URAEMIC PLATELET DYSFUNCTION.
The platelet count may be normal despite impaired haemostasis.
The original list should also include two major severe complications:
SEVERE METABOLIC ACIDOSIS
and
URAEMIC ENCEPHALOPATHY/PERICARDITIS.
Key Clinical Pattern
The severe complications of AKI can be remembered as:
POTASSIUM → HYPERKALAEMIA.
FLUID → DEPLETION OR OVERLOAD.
LUNGS → PULMONARY OEDEMA.
ACID → METABOLIC ACIDOSIS.
URAEMIA → ENCEPHALOPATHY + PERICARDITIS + BLEEDING.
The complications most likely to trigger urgent dialysis are:
REFRACTORY HYPERKALAEMIA.
REFRACTORY PULMONARY OEDEMA.
SEVERE REFRACTORY METABOLIC ACIDOSIS.
SYMPTOMATIC URAEMIA – especially encephalopathy, pericarditis or significant bleeding.
- Published on
Click here to start customizing
- Published on
Medicine – Criteria for Urgent Dialysis
Urgent dialysis, more broadly called urgent kidney replacement therapy (KRT), is required when severe complications of kidney failure cannot be adequately or rapidly controlled with medical treatment.
The decision to start dialysis should not be based on the serum creatinine or urea concentration alone. The most important consideration is whether the patient has dangerous complications such as refractory hyperkalaemia, pulmonary oedema, severe metabolic acidosis or symptomatic uraemia.
1. Major Indications for Urgent Dialysis
The classic indications can be remembered using the mnemonic:
AEIOU
A – Acidosis.
E – Electrolyte disturbance, especially hyperkalaemia.
I – Intoxication with selected dialysable substances.
O – Overload of fluid.
U – Uraemic complications.
2. Severe Hyperkalaemia
Severe hyperkalaemia is one of the most important indications for urgent dialysis because a markedly elevated serum potassium can cause:
Life-threatening cardiac arrhythmias.
The risk is particularly high when hyperkalaemia is accompanied by:
ECG abnormalities.
3. ECG Changes in Hyperkalaemia
Progressive hyperkalaemia may produce:
Tall peaked T waves.
PR prolongation.
Loss or flattening of P waves.
QRS widening.
Sine-wave pattern in extreme cases.
This can progress to:
Ventricular arrhythmia or cardiac arrest.
4. Initial Treatment of Hyperkalaemia
Severe hyperkalaemia requires immediate medical treatment while dialysis is being arranged when necessary.
Treatment may include:
Intravenous calcium to stabilise the cardiac membrane when indicated.
Insulin with glucose to shift potassium into cells.
Nebulised beta₂-agonist as an additional intracellular potassium-shifting treatment.
Correction of significant acidosis when appropriate.
However, these measures often provide only temporary control because they do not necessarily remove enough potassium from the body.
5. When Hyperkalaemia Requires Dialysis
Urgent dialysis is particularly important when hyperkalaemia is:
Severe.
Associated with dangerous ECG changes.
Persistent despite appropriate medical treatment.
Recurrent after temporary treatment.
Therefore, the high-yield indication is:
REFRACTORY OR LIFE-THREATENING HYPERKALAEMIA → URGENT DIALYSIS.
6. Fluid Overload
Kidney failure can severely impair:
Sodium and water excretion.
This leads to expansion of extracellular fluid volume.
Clinical manifestations include:
Peripheral oedema.
Hypertension.
Raised jugular venous pressure.
Pulmonary congestion.
7. Pulmonary Oedema
The most dangerous consequence of fluid overload is:
Pulmonary oedema.
Fluid accumulates within the lungs, impairing:
Gas exchange.
The patient may develop:
Severe breathlessness.
Orthopnoea.
Hypoxaemia.
Fine inspiratory crackles.
Respiratory distress.
8. When Fluid Overload Requires Dialysis
Initial treatment may include:
Oxygen or ventilatory support when required.
Fluid and sodium management.
Loop diuretics when the patient is capable of responding.
However, urgent dialysis is indicated when severe fluid overload or pulmonary oedema is:
Refractory to appropriate medical treatment.
Therefore:
REFRACTORY PULMONARY OEDEMA → URGENT DIALYSIS.
9. Metabolic Acidosis
Healthy kidneys maintain acid-base balance by:
Excreting hydrogen ions
and
Regenerating bicarbonate.
Severe renal failure reduces this capacity and can produce:
Metabolic acidosis.
10. Consequences of Severe Acidosis
Severe metabolic acidosis can cause:
Reduced myocardial contractility.
Peripheral vasodilatation.
Hypotension.
Reduced responsiveness to catecholamines.
Cardiovascular instability.
It can also worsen:
Hyperkalaemia.
11. When Acidosis Requires Dialysis
The original note describes:
“Acidosis resulting in circulatory compromise.”
This is an important indication.
More generally, dialysis should be considered when metabolic acidosis is:
Severe
and
Refractory to appropriate medical treatment,
particularly when accompanied by:
Haemodynamic or circulatory compromise.
Therefore:
SEVERE REFRACTORY METABOLIC ACIDOSIS → URGENT DIALYSIS.
12. Uraemia
Uraemia is the clinical syndrome caused by accumulation of uraemic toxins and the metabolic consequences of severe kidney failure.
It is not simply:
A high serum urea concentration.
Instead, uraemia refers to the development of:
Clinical manifestations of advanced kidney failure.
13. Uraemic Encephalopathy
Severe uraemia can impair cerebral function and cause:
Uraemic encephalopathy.
Features may include:
Confusion.
Reduced concentration.
Drowsiness.
Altered consciousness.
Asterixis.
Seizures in severe cases.
14. Uraemic Encephalopathy and Dialysis
Uraemic encephalopathy is a major indication for:
Urgent dialysis.
Without treatment, neurological deterioration can become severe.
Therefore:
URAEMIA + ENCEPHALOPATHY → URGENT DIALYSIS.
15. Uraemic Pericarditis
Advanced uraemia can cause inflammation of the:
Pericardium.
This is called:
Uraemic pericarditis.
Patients may develop:
Chest pain.
Pericardial friction rub.
Pericardial effusion.
16. Complications of Uraemic Pericarditis
A significant pericardial effusion may progress to:
Cardiac tamponade.
Therefore uraemic pericarditis is an important indication for:
Urgent dialysis.
17. Uraemic Bleeding
Kidney failure can cause:
Platelet dysfunction.
Platelet numbers may be relatively normal, but platelet adhesion and aggregation are impaired.
This produces a:
Uraemic bleeding tendency.
18. Manifestations of Uraemic Bleeding
Possible manifestations include:
Easy bruising.
Epistaxis.
Gastrointestinal bleeding.
Bleeding from puncture sites.
Other clinically significant haemorrhage.
Severe uraemic bleeding can be an indication for:
Urgent dialysis.
19. Other Uraemic Symptoms
Other severe or refractory manifestations of uraemia can also contribute to the decision to initiate dialysis.
These may include:
Persistent nausea and vomiting.
Severe anorexia.
Progressive malnutrition.
Severe pruritus.
Peripheral neuropathy.
The overall clinical picture determines the need for kidney replacement therapy.
20. Intoxication – An Additional Indication
An important indication not included in the original notes is:
Certain severe poisonings or drug intoxications.
Dialysis can remove selected substances from the circulation.
This forms the:
“I” in AEIOU.
21. Dialysable Toxins
Examples where extracorporeal removal may be useful in appropriate severe poisoning include:
Lithium.
Methanol.
Ethylene glycol.
Salicylates.
Some other toxins and medications may also be dialysable depending on their pharmacological characteristics and the clinical situation.
22. Why Some Toxins Can Be Dialysed
Haemodialysis is particularly effective for substances that have characteristics such as:
Low molecular weight.
Low protein binding.
Small volume of distribution.
High water solubility.
However, the decision depends on the particular toxin, concentration and clinical severity.
23. Creatinine Alone Is Not an Indication
A very high:
Serum creatinine
does not automatically mean the patient requires emergency dialysis.
Similarly, there is no universal creatinine concentration at which every patient must begin dialysis.
24. Urea Alone Is Not an Indication
A high:
Serum urea
also does not automatically mandate urgent dialysis.
The decision is primarily based on:
Symptoms.
Complications.
Biochemical abnormalities.
Volume status.
Response to medical therapy.
Overall clinical condition.
25. Oliguria Alone Is Not Necessarily an Indication
Severe:
Oliguria
or
Anuria
greatly increases the risk of hyperkalaemia, acidosis and fluid overload.
However, urine output alone does not always determine the need for dialysis.
The important question is whether dangerous complications are:
Present or developing.
26. AKI and Urgent Dialysis
In acute kidney injury, urgent dialysis may therefore be required for:
Refractory hyperkalaemia.
Severe refractory metabolic acidosis.
Refractory pulmonary oedema.
Uraemic complications.
Selected intoxications.
27. CKD and Urgent Dialysis
The same life-threatening complications can occur in:
Advanced chronic kidney disease.
A patient with CKD may therefore require urgent dialysis if they develop:
Severe hyperkalaemia.
Pulmonary oedema.
Severe acidosis.
Uraemic encephalopathy.
Uraemic pericarditis.
Clinically significant uraemic bleeding.
28. Haemodialysis
Haemodialysis removes solutes and excess fluid by passing blood through an extracorporeal:
Dialyser.
It can rapidly correct:
Hyperkalaemia.
Metabolic acidosis.
Fluid overload.
Accumulation of many uraemic solutes.
29. Continuous Kidney Replacement Therapy
Critically ill patients who are severely:
Haemodynamically unstable
may sometimes be treated using:
Continuous kidney replacement therapy – CKRT/CRRT.
This removes fluid and solutes more gradually than conventional intermittent haemodialysis.
The choice of modality depends on the clinical setting.
30. Urgent Dialysis – AEIOU Note Form
A – Acidosis
Severe metabolic acidosis.
Refractory to appropriate medical treatment.
Especially important when causing haemodynamic compromise.
E – Electrolytes
Severe hyperkalaemia.
Dangerous ECG abnormalities.
Persistent or recurrent despite appropriate medical therapy.
I – Intoxication
Selected dialysable toxins.
Examples include severe poisoning with lithium, methanol, ethylene glycol or salicylates in appropriate circumstances.
O – Overload
Severe fluid overload.
Pulmonary oedema.
Refractory to appropriate medical therapy.
U – Uraemia
Uraemic encephalopathy.
Uraemic pericarditis.
Clinically significant uraemic bleeding.
Other severe refractory uraemic manifestations.
31. Important Corrections to the Original Notes
The original criterion:
“Severe hyperkalaemia”
is correct, but the most important situation is:
LIFE-THREATENING OR REFRACTORY HYPERKALAEMIA.
The original criterion:
“Fluid overload leading to pulmonary oedema”
is correct and can be refined to:
PULMONARY OEDEMA/SEVERE FLUID OVERLOAD THAT CANNOT BE ADEQUATELY CONTROLLED MEDICALLY.
The original criterion:
“Acidosis resulting in circulatory compromise”
is also correct.
A broader modern formulation is:
SEVERE REFRACTORY METABOLIC ACIDOSIS, ESPECIALLY WITH HAEMODYNAMIC COMPROMISE.
The original uraemic indications are particularly important:
ENCEPHALOPATHY.
PERICARDITIS.
CLINICALLY SIGNIFICANT BLEEDING.
The major missing indication from the original list is:
SELECTED INTOXICATIONS.
Key Clinical Pattern
The easiest way to remember urgent dialysis indications is:
AEIOU
A → ACIDOSIS
E → ELECTROLYTES – especially hyperkalaemia
I → INTOXICATION
O → OVERLOAD – especially pulmonary oedema
U → URAEMIA – encephalopathy, pericarditis, bleeding
The four especially important renal emergencies are:
REFRACTORY HYPERKALAEMIA.
REFRACTORY PULMONARY OEDEMA.
SEVERE REFRACTORY METABOLIC ACIDOSIS.
SYMPTOMATIC URAEMIA.
And remember:
DIALYSE THE PATIENT FOR THE CLINICAL/PHYSIOLOGICAL INDICATION — NOT SIMPLY FOR A HIGH CREATININE OR UREA VALUE.
- Published on
Medicine – Rhabdomyolysis
Rhabdomyolysis is a syndrome caused by rapid breakdown and necrosis of skeletal muscle fibres, resulting in the release of intracellular muscle contents into the circulation.
Important substances released include:
Myoglobin.
Creatine kinase – CK.
Potassium.
Phosphate.
Uric acid and other intracellular constituents.
The most important complications are acute kidney injury (AKI) and potentially life-threatening hyperkalaemia.
1. Basic Pathophysiology
Skeletal muscle injury causes disruption of the muscle-cell membrane.
As muscle cells break down, their intracellular contents enter the bloodstream.
Therefore:
Muscle injury → muscle-cell necrosis → release of CK + myoglobin + potassium + phosphate → systemic complications.
2. Myoglobin Release
Myoglobin is an oxygen-binding protein found within skeletal muscle.
When large amounts of skeletal muscle are damaged, myoglobin enters the:
Bloodstream
and is subsequently filtered through the:
Glomeruli.
Large quantities of filtered myoglobin can contribute to:
Acute tubular injury and AKI.
3. Acute Kidney Injury
The older term:
Acute renal failure – ARF
should now be replaced by:
Acute kidney injury – AKI.
AKI is one of the most important complications of severe rhabdomyolysis.
4. Mechanisms of AKI
Several mechanisms contribute simultaneously.
Myoglobin can cause:
Direct tubular toxicity.
Intratubular cast formation and obstruction.
Oxidative tubular injury.
In addition, fluid moves into injured muscle, producing:
Intravascular volume depletion.
Renal vasoconstriction and reduced renal perfusion further increase the risk of:
AKI.
5. Hypovolaemia
Damaged muscles can become markedly:
Oedematous.
Large quantities of fluid may move from the circulation into injured muscle.
This produces:
Third-space fluid loss → reduced circulating volume → reduced renal perfusion.
Therefore, hypovolaemia contributes importantly to kidney injury.
6. Clinical Presentation
The classic symptoms are:
Muscle pain.
Muscle weakness.
Muscle swelling.
Dark urine.
However, the complete classic presentation is not present in every patient.
Some patients have few obvious muscular symptoms and are diagnosed because of:
Markedly elevated CK.
7. Muscle Pain
Patients may develop:
Myalgia
or severe muscle tenderness.
The muscles affected depend on the underlying cause.
For example, prolonged compression may produce localised severe muscle injury, whereas seizures can cause more widespread muscle breakdown.
8. Muscle Weakness
Muscle injury may produce:
Generalised or localised weakness.
Weakness may be accompanied by:
Tenderness
and
Swelling.
9. Dark Urine
Myoglobin filtered into the urine can produce:
Dark brown
or
Tea/cola-coloured urine.
This is called:
Myoglobinuria.
10. Myoglobinuria and Urine Dipstick
An important examination finding is:
Urine dipstick positive for “blood”
but
Urine microscopy showing few or no red blood cells.
This occurs because the dipstick detects the haem pigment in:
Myoglobin
as well as haemoglobin.
11. High-Yield Urine Pattern
Therefore:
Dark urine + positive dipstick for blood + few/no RBCs on microscopy → think myoglobinuria from rhabdomyolysis.
However, this finding is not sufficiently sensitive to exclude rhabdomyolysis when absent.
12. Creatine Kinase
The most important biochemical marker is:
Creatine kinase – CK.
Rhabdomyolysis produces a:
Marked elevation of CK.
CK may reach:
Thousands or tens of thousands of units per litre
in severe cases.
13. Diagnostic CK Elevation
There is no single CK value that perfectly defines every case, but rhabdomyolysis is commonly considered when CK is approximately:
>5 times the upper limit of normal
in an appropriate clinical setting.
The greater the muscle injury, the higher CK generally becomes.
14. CK versus Myoglobin
Myoglobin rises and disappears from the circulation relatively quickly.
CK remains elevated for longer.
Therefore:
CK is generally more useful for diagnosis and monitoring than serum or urinary myoglobin.
15. Hyperkalaemia
Skeletal muscle contains large amounts of intracellular:
Potassium.
Muscle-cell destruction releases potassium into the circulation.
Therefore rhabdomyolysis can produce:
Hyperkalaemia.
16. Why Hyperkalaemia Is Dangerous
Severe hyperkalaemia can cause:
Cardiac conduction abnormalities.
Ventricular arrhythmias.
Cardiac arrest.
Therefore potassium should be assessed urgently in significant rhabdomyolysis.
17. Hyperphosphataemia
Muscle cells also contain large amounts of:
Phosphate.
Cell destruction releases phosphate into the bloodstream, causing:
Hyperphosphataemia.
18. Hypocalcaemia
During the early phase of rhabdomyolysis, calcium may move into damaged muscle and precipitate with phosphate.
This can cause:
Hypocalcaemia.
Therefore the typical early biochemical pattern may include:
↑ Potassium.
↑ Phosphate.
↓ Calcium.
19. Calcium During Recovery
During recovery, calcium deposited in damaged muscle may return to the circulation.
Some patients can therefore develop:
Rebound hypercalcaemia.
This is an important reason calcium abnormalities can change during the course of rhabdomyolysis.
20. Uric Acid
Breakdown of muscle cells and nucleic acids can increase:
Uric acid.
Hyperuricaemia may further contribute to renal tubular injury in severe disease.
21. Creatinine
The original notes state:
“Creatinine raised disproportionately to urea.”
This can occur because skeletal muscle breakdown releases:
Creatine and creatinine precursors.
Therefore creatinine may rise relatively rapidly compared with urea.
However, this is not required for diagnosis and should not replace CK measurement and assessment of kidney function.
22. Other Laboratory Abnormalities
Rhabdomyolysis may also produce:
Raised AST.
Raised LDH.
Metabolic acidosis.
AST can originate from skeletal muscle, so an elevated AST does not necessarily indicate primary liver injury.
23. Major Causes
Rhabdomyolysis has many causes.
They can broadly be grouped into:
Traumatic.
Exertional.
Drug-related.
Toxic.
Metabolic.
Seizure-related.
Thermal.
Infectious.
24. Trauma and Compression Injury
Severe:
Trauma
or
Compression injury
can cause extensive muscle necrosis.
Examples include:
Crush injuries.
Building collapse.
Road traffic trauma.
Prolonged entrapment.
25. Crush Syndrome
When extensive compression produces rhabdomyolysis together with systemic complications, the condition may be described as:
Crush syndrome.
After the pressure is released, large amounts of:
Potassium, myoglobin and other intracellular substances
may rapidly enter the circulation.
This can cause severe:
Hyperkalaemia
and
AKI.
26. Prolonged Immobilisation
Prolonged pressure on muscle can also occur when a person remains unconscious or immobile for many hours.
Examples include prolonged immobilisation associated with:
Drug intoxication.
Alcohol intoxication.
Coma.
This causes:
Pressure-induced muscle ischaemia and necrosis.
27. Seizures
The original term:
“Uncontrolled fitting”
is better expressed as:
Prolonged or repeated generalised seizures.
Intense repetitive skeletal-muscle contraction can cause extensive muscle breakdown.
Therefore:
Status epilepticus → muscle injury → rhabdomyolysis.
28. Excessive Exercise
Severe or unaccustomed physical exertion can cause:
Exertional rhabdomyolysis.
Risk is increased by:
Extreme exercise.
Heat.
Dehydration.
Underlying metabolic or genetic muscle disorders.
29. Statins
Statins can rarely cause severe muscle injury leading to:
Rhabdomyolysis.
More commonly they cause milder:
Myalgia
or
CK elevation.
True statin-associated rhabdomyolysis is uncommon but potentially serious.
30. Risk Factors for Statin-Associated Rhabdomyolysis
Risk may increase with:
High statin exposure.
Drug interactions that increase statin concentrations.
Advanced age.
Renal impairment.
Hypothyroidism.
Certain combinations of lipid-lowering drugs.
31. Drugs and Toxins
Many other substances can cause rhabdomyolysis.
Examples include:
Cocaine.
Amphetamines.
Some antipsychotic-related syndromes.
Alcohol, particularly with prolonged immobilisation.
The mechanism varies between:
Direct toxicity, hyperthermia, seizures, agitation and immobilisation.
32. Neuroleptic Malignant Syndrome
Neuroleptic malignant syndrome can cause:
Severe muscle rigidity.
Hyperthermia.
Autonomic instability.
Marked CK elevation.
Rhabdomyolysis can therefore be an important complication.
33. Burns
Severe:
Burns
can produce extensive muscle and tissue injury.
They may therefore be associated with:
Rhabdomyolysis
particularly when the injury is deep or associated with electrical damage.
34. Electrical Injury
Electrical injury is particularly important because substantial deep muscle damage can occur even when external skin injury appears relatively limited.
Therefore:
Electrical injury → deep muscle necrosis → rhabdomyolysis → hyperkalaemia + AKI.
35. Heat-Related Illness
Severe hyperthermia, particularly:
Heatstroke,
can cause extensive skeletal-muscle injury.
Heatstroke-associated rhabdomyolysis may coexist with:
Neurological dysfunction.
Coagulopathy.
Hepatic injury.
AKI.
36. Infections
Some severe infections can precipitate rhabdomyolysis.
Both:
Viral
and
Bacterial infections
have been associated with muscle breakdown.
The mechanism may involve direct muscle injury, inflammation, fever and systemic illness.
37. Metabolic and Electrolyte Causes
Severe electrolyte abnormalities may occasionally cause rhabdomyolysis.
Examples include marked disturbances of:
Potassium.
Phosphate.
Sodium.
Endocrine abnormalities such as severe:
Hypothyroidism
can also predispose to muscle injury.
38. Inherited Muscle Disorders
Recurrent episodes of rhabdomyolysis, particularly after exercise or fasting, may suggest an underlying:
Metabolic myopathy.
Examples include disorders of:
Glycogen metabolism.
Fatty-acid oxidation.
Mitochondrial metabolism.
These become particularly relevant when episodes are recurrent without an obvious acquired cause.
39. Compartment Syndrome
Severe muscle swelling can increase pressure within a closed fascial compartment.
This may produce:
Compartment syndrome.
Increasing pressure compromises:
Muscle and nerve perfusion.
This creates further ischaemia and muscle necrosis.
40. Compartment Syndrome Is an Emergency
Features include:
Severe pain, especially pain out of proportion to the injury.
Pain on passive stretch.
Tense swollen compartment.
Neurological abnormalities as disease progresses.
Suspected acute compartment syndrome requires:
Urgent surgical assessment.
41. Major Complications
Important complications of rhabdomyolysis include:
Acute kidney injury.
Hyperkalaemia.
Hyperphosphataemia.
Early hypocalcaemia.
Metabolic acidosis.
Cardiac arrhythmias.
Compartment syndrome.
Disseminated intravascular coagulation in severe systemic disease.
42. Initial Assessment
Investigation should determine both:
The severity of muscle injury
and
The presence of complications.
Important tests include:
CK.
Creatinine and renal function.
Potassium.
Phosphate.
Calcium.
Bicarbonate.
Urinalysis.
43. ECG
Because hyperkalaemia can be rapidly fatal, an:
ECG
is important when significant hyperkalaemia is present or suspected.
ECG abnormalities may include:
Peaked T waves.
PR prolongation.
QRS widening.
Progression to malignant arrhythmias.
44. Management
The cornerstone of treatment is:
Early intravenous crystalloid fluid administration
when clinically appropriate.
The aim is to:
Correct intravascular volume depletion.
Maintain renal perfusion.
Promote urinary excretion of myoglobin.
45. Intravenous Fluids
Fluid therapy is generally based on:
Isotonic crystalloid.
The exact volume and rate should be individualised according to:
Severity of rhabdomyolysis.
Urine output.
Haemodynamic status.
Cardiac function.
Renal function.
46. Avoid Fluid Overload
Aggressive fluid replacement must be used carefully in patients who develop:
Oliguric AKI
or who have:
Heart failure.
If the kidneys cannot excrete the administered fluid, excessive treatment may cause:
Pulmonary oedema.
Therefore fluid therapy requires close monitoring.
47. Treat the Underlying Cause
The precipitating cause should be identified and corrected.
Examples include:
Stopping an offending drug.
Treating seizures.
Treating hyperthermia.
Correcting severe electrolyte abnormalities.
Treating infection.
Managing trauma or compartment syndrome.
48. Hyperkalaemia Treatment
Severe hyperkalaemia requires:
Urgent treatment.
Management depends on potassium concentration, ECG findings and clinical severity.
The key principle is:
Rhabdomyolysis + severe hyperkalaemia = medical emergency.
49. Calcium Replacement
Although early hypocalcaemia may occur, asymptomatic hypocalcaemia is not necessarily corrected routinely, because calcium may later rebound during recovery.
Calcium treatment is generally reserved for appropriate clinical indications such as:
Symptomatic hypocalcaemia
or particular emergency circumstances.
50. Bicarbonate and Mannitol
Older protocols sometimes routinely recommended:
Urinary alkalinisation with bicarbonate
and
Mannitol.
These are not routinely required for every patient, because evidence of benefit over appropriate crystalloid resuscitation is limited.
The central treatment remains:
Appropriate IV fluids + electrolyte management + treatment of the cause.
51. Dialysis
Some patients develop severe AKI requiring:
Kidney replacement therapy – dialysis.
Dialysis may be required for standard indications such as:
Refractory hyperkalaemia.
Severe metabolic acidosis.
Refractory fluid overload.
Severe uraemic complications.
52. Dialysis Is Not Based on CK Alone
A massively elevated CK does not by itself indicate a need for dialysis.
The decision is based primarily on:
Renal function and complications.
Therefore:
High CK ≠ automatic dialysis.
53. Monitoring
Patients with significant rhabdomyolysis require repeated assessment of:
CK.
Creatinine.
Urine output.
Potassium.
Calcium.
Phosphate.
Acid-base status.
Monitoring is particularly important because electrolyte abnormalities can change rapidly.
54. Rhabdomyolysis – Causes Note Form
Traumatic:
Crush injury.
Major trauma.
Prolonged compression.
Prolonged immobilisation.
Muscular overactivity:
Generalised seizures.
Status epilepticus.
Extreme exercise.
Severe agitation.
Drugs and toxins:
Statins.
Cocaine.
Amphetamines.
Alcohol-associated immobilisation.
Other myotoxic drugs.
Thermal/electrical:
Burns.
Electrical injury.
Heatstroke.
Other:
Severe infections.
Electrolyte abnormalities.
Hypothyroidism.
Metabolic myopathies.
Inherited muscle disorders.
55. Rhabdomyolysis – Laboratory Pattern Note Form
Creatine kinase:
Massively elevated.
Most useful biochemical marker.
Potassium:
Raised because damaged muscle releases intracellular potassium.
Potentially life-threatening.
Phosphate:
Raised because phosphate is released from damaged muscle.
Calcium:
Often low early.
May become high during recovery.
Creatinine:
May rise rapidly, particularly when AKI develops.
Urine:
Dark because of myoglobin.
Dipstick may be positive for blood despite few or no RBCs on microscopy.
56. Rhabdomyolysis – Management Note Form
First:
Identify and remove the cause.
Fluids:
Early appropriate IV crystalloid.
Maintain circulating volume and renal perfusion.
Monitor carefully for fluid overload.
Electrolytes:
Monitor potassium, phosphate and calcium.
Treat severe hyperkalaemia urgently.
Kidneys:
Monitor creatinine and urine output.
Watch for AKI.
Compartment syndrome:
Urgent surgical assessment if suspected.
Dialysis:
Use when standard indications develop, particularly refractory hyperkalaemia, severe acidosis or fluid overload.
57. Important Corrections to the Original Notes
The term:
“ARF”
should be replaced by:
ACUTE KIDNEY INJURY – AKI.
The definition:
“Muscle damage or necrosis leading to myoglobin release”
is correct but can be expanded to:
SKELETAL MUSCLE BREAKDOWN → RELEASE OF MYOGLOBIN + CK + POTASSIUM + PHOSPHATE AND OTHER INTRACELLULAR CONTENTS.
The statement:
“Creatinine raised disproportionately to urea”
can occur but is not a defining diagnostic feature.
The most important biochemical marker is:
MARKEDLY ELEVATED CK.
The original biochemical features should also include:
EARLY HYPOCALCAEMIA
and potentially:
LATER REBOUND HYPERCALCAEMIA.
The cause:
“Uncontrolled fitting”
is better expressed as:
PROLONGED OR REPEATED GENERALISED SEIZURES / STATUS EPILEPTICUS.
Key Clinical Pattern
The central sequence is:
SKELETAL MUSCLE NECROSIS
↓
↑ CK + MYOGLOBIN RELEASE
↓
MYOGLOBINURIA
↓
TUBULAR INJURY + HYPOVOLAEMIA
↓
ACUTE KIDNEY INJURY
At the same time:
MUSCLE NECROSIS → ↑ POTASSIUM + ↑ PHOSPHATE → ↓ CALCIUM EARLY.
The classic examination clues are:
MUSCLE PAIN/WEAKNESS + DARK URINE + MASSIVELY ↑ CK.
And remember:
URINE DIPSTICK POSITIVE FOR BLOOD + FEW/NO RBCs = THINK MYOGLOBIN.
The most immediately dangerous biochemical complication is:
HYPERKALAEMIA → ARRHYTHMIA.
The cornerstone of management is:
EARLY APPROPRIATE IV CRYSTALLOID + TREAT THE CAUSE + MONITOR/TREAT ELECTROLYTES + WATCH FOR AKI.
- Published on
Medicine – Chronic Kidney Disease
Chronic kidney disease (CKD) is the modern term that has largely replaced chronic renal failure (CRF). CKD describes persistent abnormalities of kidney structure or function that are present for at least 3 months and have implications for health.
CKD can gradually lead to loss of functioning nephrons, reduced glomerular filtration rate (GFR), accumulation of metabolic waste products, disturbances of fluid and electrolyte balance, endocrine abnormalities, cardiovascular complications and eventually end-stage kidney disease (ESKD).
1. Definition of Chronic Kidney Disease
CKD is present when, for at least 3 months, there is either:
Reduced GFR
or
Evidence of kidney damage.
A commonly used GFR criterion is:
eGFR <60 mL/min/1.73 m² for at least 3 months.
However, a patient can have CKD despite an eGFR above 60 if there is persistent evidence of kidney damage, such as:
Albuminuria.
Abnormal urinary sediment.
Structural kidney abnormalities.
Histological abnormalities.
2. CKD versus Chronic Renal Failure
The older term:
Chronic renal failure – CRF
usually referred to relatively advanced loss of kidney function.
The preferred modern term is:
Chronic kidney disease – CKD.
CKD includes the entire spectrum from relatively mild chronic kidney damage to:
Kidney failure / ESKD.
3. Major Causes of CKD
The original notes give historical UK percentages for individual causes.
These percentages should not be memorised as fixed current values because the distribution changes over time and depends on whether statistics refer to:
All CKD
or
Patients reaching kidney replacement therapy.
The important causes include:
Diabetes mellitus.
Hypertension and vascular disease.
Glomerular disease.
Inherited kidney disease.
Reflux and congenital urinary tract disease.
Chronic obstruction.
Tubulointerstitial disease.
Plasma-cell disorders.
4. Diabetes Mellitus
Diabetes mellitus is one of the most important causes of CKD and kidney failure.
Persistent hyperglycaemia damages the glomerular filtration barrier and produces:
Diabetic kidney disease.
5. Diabetic Kidney Disease
The pathological changes include:
Glomerular basement membrane thickening.
Mesangial expansion.
Glomerular hyperfiltration and intraglomerular hypertension early in disease.
Progressive glomerulosclerosis.
A classic advanced lesion is:
Kimmelstiel–Wilson nodular glomerulosclerosis.
6. Clinical Progression of Diabetic Kidney Disease
Patients may develop:
Albuminuria.
Proteinuria.
Hypertension.
Progressive decline in GFR.
Eventually, some patients progress to:
ESKD.
However, CKD progression can also occur in diabetes without marked albuminuria.
7. Chronic Glomerulonephritis
Chronic glomerular diseases are another important cause of CKD.
Examples include:
IgA nephropathy.
FSGS.
Membranous nephropathy.
Lupus nephritis.
MPGN and C3 glomerulopathy.
Repeated or persistent glomerular injury eventually causes:
Glomerulosclerosis and nephron loss.
8. Hypertension and Vascular Kidney Disease
Long-standing hypertension can contribute to progressive kidney damage.
Chronic vascular injury causes:
Arteriolar narrowing.
Renal ischaemia.
Glomerulosclerosis.
Tubular atrophy.
Interstitial fibrosis.
This is traditionally described as:
Hypertensive nephrosclerosis.
9. The Kidney–Hypertension Cycle
CKD itself also causes hypertension through:
Sodium retention.
Water retention.
RAAS activation.
Therefore:
Hypertension damages the kidney → kidney disease worsens hypertension → hypertension accelerates CKD.
Breaking this cycle is an important goal of treatment.
10. Renovascular Disease
Atherosclerotic narrowing of the renal arteries may cause:
Renovascular hypertension
and
Ischaemic nephropathy.
Progressive bilateral disease, particularly in patients with widespread atherosclerosis, can contribute to CKD.
11. Reflux Nephropathy
Reflux nephropathy results from renal scarring associated with:
Vesicoureteric reflux, often combined with recurrent urinary infection.
It is particularly important when reflux begins during:
Childhood.
12. Consequences of Reflux Nephropathy
Progressive renal scarring may produce:
Proteinuria.
Hypertension.
Reduced renal function.
CKD.
Severe bilateral disease can eventually cause:
ESKD.
13. Polycystic Kidney Disease
Autosomal dominant polycystic kidney disease – ADPKD is an important inherited cause of CKD.
Progressive development and enlargement of renal cysts causes:
Kidney enlargement.
Hypertension.
Haematuria.
Pain.
Recurrent infections.
Stones.
Progressive loss of renal function.
14. ADPKD and ESKD
Some patients with ADPKD eventually progress to:
ESKD
and require:
Dialysis
or
Kidney transplantation.
Important extrarenal associations include:
Hepatic cysts
and
Intracranial saccular aneurysms.
15. Chronic Urinary Tract Obstruction
Long-standing urinary obstruction can cause:
Hydronephrosis.
Tubular atrophy.
Interstitial fibrosis.
Progressive nephron loss.
This is sometimes called:
Post-obstructive nephropathy.
16. Causes of Chronic Obstruction
Possible causes include:
Benign prostatic enlargement.
Urinary tract malignancy.
Ureteric obstruction.
Stones.
Urethral stricture.
Neurogenic bladder.
Bilateral obstruction or obstruction affecting a solitary functioning kidney is particularly important.
17. Multiple Myeloma
Multiple myeloma can cause CKD through several mechanisms.
These include:
Light-chain cast nephropathy.
AL amyloidosis.
Monoclonal immunoglobulin deposition disease.
Hypercalcaemia.
Recurrent infection.
18. Myeloma Kidney
Excess monoclonal light chains can pass through the glomerulus and interact with proteins within the renal tubules.
This can produce:
Obstructing casts
and
Tubular injury.
This is called:
Light-chain cast nephropathy.
19. Amyloidosis
Amyloidosis can cause progressive renal disease through deposition of:
Amyloid fibrils within the kidney.
Renal amyloidosis often initially causes:
Heavy proteinuria
or
Nephrotic syndrome.
Progressive damage may eventually result in:
CKD and ESKD.
20. Chronic Tubulointerstitial Nephritis
Chronic tubulointerstitial nephritis primarily damages:
Renal tubules
and
Interstitial tissue.
Over time, this causes:
Tubular atrophy.
Interstitial fibrosis.
Progressive decline in renal function.
21. Causes of Chronic Tubulointerstitial Disease
Possible causes include:
Chronic drug exposure.
Lithium.
Chronic obstruction.
Reflux nephropathy.
Certain metabolic disorders.
Some autoimmune diseases.
22. Analgesic Nephropathy
Analgesic nephropathy is a form of chronic tubulointerstitial injury associated historically with prolonged consumption of certain analgesic combinations.
Classically it can produce:
Chronic interstitial nephritis
and
Renal papillary necrosis.
Its epidemiology has changed substantially following withdrawal or restriction of older analgesic preparations.
23. Renal Calculi
Recurrent or extensive:
Renal calculi
can contribute to CKD, particularly when associated with:
Recurrent obstruction.
Recurrent infection.
Staghorn calculi.
Bilateral disease.
An isolated uncomplicated kidney stone does not usually cause CKD.
24. CKD after Acute Kidney Injury
The original notes use:
“Post-ARF.”
The modern term is:
CKD following acute kidney injury – AKI.
Severe or repeated AKI can result in incomplete renal recovery and subsequent:
CKD.
25. AKI and CKD Are Closely Related
AKI increases the future risk of:
CKD.
At the same time, pre-existing CKD increases susceptibility to:
AKI.
Therefore:
AKI and CKD can form a mutually reinforcing cycle of kidney injury.
26. Clinical Features of CKD
Early CKD may be:
Completely asymptomatic.
As renal function declines, patients may develop:
Fatigue.
Anorexia.
Nausea.
Pruritus.
Oedema.
Breathlessness.
Nocturia.
Hypertension.
Muscle cramps.
Reduced exercise tolerance.
27. Advanced CKD and Uraemia
Advanced kidney failure can cause:
Uraemia.
Possible manifestations include:
Anorexia.
Nausea and vomiting.
Pruritus.
Cognitive disturbance.
Peripheral neuropathy.
Pericarditis.
Bleeding tendency due to platelet dysfunction.
Severe symptomatic uraemia may indicate a need for:
Kidney replacement therapy.
28. Major Complications of CKD
Important complications include:
Hypertension.
Fluid overload.
Hyperkalaemia.
Metabolic acidosis.
Anaemia.
CKD-mineral and bone disorder.
Cardiovascular disease.
Malnutrition in advanced disease.
29. Management of CKD
Management has several major goals:
Identify and treat the underlying cause.
Slow progression of kidney disease.
Reduce proteinuria or albuminuria.
Control cardiovascular risk.
Treat CKD complications.
Avoid further renal injury.
Prepare appropriately for kidney replacement therapy when necessary.
30. Blood Pressure Control
Blood-pressure control is one of the most important interventions for slowing CKD progression and reducing:
Cardiovascular risk.
The original notes give a universal target of:
<130/75 mmHg.
This is an older simplified target.
Modern blood-pressure targets are more:
Individualised
and depend on factors such as:
Albuminuria.
Diabetes.
Age.
Cardiovascular disease.
Treatment tolerance.
31. ACE Inhibitors
ACE inhibitors reduce systemic blood pressure and also dilate the:
Efferent arteriole.
This reduces:
Intraglomerular pressure.
As a result, ACE inhibitors can reduce:
Albuminuria and proteinuria.
32. ARBs
Angiotensin receptor blockers – ARBs provide similar kidney-protective effects.
Therefore:
ACE inhibitor OR ARB
is particularly important in many patients with:
Albuminuric CKD.
33. ACE Inhibitors and Creatinine
Starting an ACE inhibitor or ARB may produce a modest initial rise in:
Serum creatinine.
This occurs because efferent arteriolar dilation lowers intraglomerular pressure.
Renal function and:
Serum potassium
should therefore be monitored after initiation or dose adjustment.
34. ACE Inhibitors and Hyperkalaemia
ACE inhibitors and ARBs can increase:
Serum potassium.
This is particularly important in advanced CKD.
Therefore treatment requires monitoring of:
Potassium
and
Renal function.
35. Avoid Routine ACE Inhibitor plus ARB Combination
ACE inhibitors and ARBs should generally:
Not be routinely combined.
Dual blockade increases the risk of:
Hyperkalaemia.
Hypotension.
Acute kidney injury.
without sufficient additional benefit for most patients.
36. Other Antihypertensive Drugs
Additional drugs may be required to achieve adequate blood-pressure control.
These can include:
Calcium-channel blockers.
Diuretics.
Beta blockers in selected patients.
Other agents may be added according to the patient’s clinical circumstances.
37. Diuretics
Diuretics are particularly useful when CKD is accompanied by:
Fluid retention
and
Hypertension.
Loop diuretics such as:
Furosemide
are often useful in advanced CKD with volume overload.
38. Reduction of Proteinuria
Proteinuria is not merely a marker of renal disease.
Persistent albuminuria can also contribute to:
Progressive kidney injury.
Reducing albuminuria is therefore an important therapeutic goal.
39. RAAS Blockade and Proteinuria
ACE inhibitors and ARBs reduce:
Intraglomerular pressure
and therefore:
Urinary albumin excretion.
This provides renal protection in many forms of:
Albuminuric CKD.
40. SGLT2 Inhibitors
An important modern addition to the original notes is:
Sodium-glucose cotransporter-2 – SGLT2 – inhibitors.
These drugs have become major kidney-protective therapies for many suitable patients with CKD.
Examples include:
Dapagliflozin.
Empagliflozin.
41. SGLT2 Inhibitors and Kidney Protection
SGLT2 inhibitors can:
Slow CKD progression.
Reduce albuminuria.
Reduce heart-failure events.
Reduce cardiovascular risk in appropriate patients.
Importantly, their kidney-protective benefits extend beyond glucose lowering and can apply to selected patients:
With or without diabetes.
42. Finerenone
In selected patients with:
Type 2 diabetes + CKD + persistent albuminuria,
another modern kidney-protective treatment is:
Finerenone.
Finerenone is a:
Non-steroidal mineralocorticoid receptor antagonist.
Potassium must be monitored because:
Hyperkalaemia can occur.
43. Treatment of Anaemia
Anaemia becomes increasingly common as CKD progresses.
The major mechanism is:
Relative erythropoietin deficiency.
However, iron deficiency and inflammation frequently contribute.
44. Investigation of Anaemia
Assessment should include:
Haemoglobin.
MCV.
Ferritin.
Transferrin saturation – TSAT.
Other causes such as:
B12 deficiency, folate deficiency and blood loss
should be investigated when appropriate.
45. Iron Treatment
Iron deficiency may be treated with:
Oral iron
or
Intravenous iron.
IV iron is particularly commonly used in:
Haemodialysis patients.
The original instruction to use IV iron routinely is therefore too broad.
46. Erythropoiesis-Stimulating Agents
Persistent significant CKD-related anaemia may be treated with:
Erythropoiesis-stimulating agents – ESAs.
Examples include:
Epoetin
and
Darbepoetin.
These replace the inadequate erythropoietic stimulus caused by CKD.
47. Haemoglobin Target
The original note states:
“Maintain Hb >10 g/dL.”
Modern ESA treatment does not simply aim to normalise haemoglobin.
The treatment target is:
Individualised.
Excessively raising haemoglobin with ESA therapy can increase:
Hypertension.
Thrombosis.
Cardiovascular complications.
48. Dietary Management
Dietary treatment should be:
Individualised according to the patient’s CKD stage and biochemical abnormalities.
It is incorrect to assume that every patient with CKD requires universal restriction of:
Potassium
or other nutrients.
49. Salt Intake
Reducing excessive dietary:
Sodium
can help control:
Blood pressure.
Oedema.
Fluid overload.
It can also improve the effectiveness of antihypertensive treatment.
50. Potassium Intake
The original notes recommend:
Low potassium intake.
This should not be applied automatically to every patient with CKD.
Potassium restriction is mainly required when there is:
Hyperkalaemia
or a significant risk of developing it.
Unnecessary restriction may reduce dietary quality.
51. Protein Intake
Excessive protein intake may increase:
Nitrogenous waste production
and
Intraglomerular pressure.
However, severe protein restriction can cause:
Malnutrition.
Therefore dietary protein intake should be appropriate rather than excessively restricted.
52. Calorie Intake
Adequate energy intake is important, particularly in advanced CKD.
Insufficient calorie intake can contribute to:
Protein-energy wasting.
This is associated with poorer outcomes.
53. CKD-Mineral and Bone Disorder
Reduced kidney function disturbs:
Phosphate excretion.
Vitamin D activation.
Calcium balance.
PTH regulation.
This produces:
CKD-mineral and bone disorder – CKD-MBD.
54. Hyperphosphataemia
As GFR declines, phosphate excretion becomes impaired.
Advanced CKD may therefore produce:
Hyperphosphataemia.
Management may include:
Dietary phosphate management
and
Phosphate binders.
55. Phosphate Binders
Examples include calcium-containing agents such as:
Calcium acetate
and non-calcium agents such as:
Sevelamer.
The choice depends on:
Calcium concentration.
Phosphate concentration.
PTH.
Overall calcification risk.
56. Vitamin D and Alfacalcidol
The kidney normally activates vitamin D to:
Calcitriol – 1,25-dihydroxyvitamin D.
Advanced CKD impairs this process.
Selected patients with secondary hyperparathyroidism may therefore receive:
Active vitamin D or analogues such as alfacalcidol.
These treatments require monitoring because they can increase:
Calcium and phosphate.
57. Secondary Hyperparathyroidism
CKD causes:
Phosphate retention + reduced calcitriol + altered calcium regulation → increased PTH.
This produces:
Secondary hyperparathyroidism.
Persistent severe disease contributes to:
Renal osteodystrophy.
58. Calcimimetics
Selected dialysis patients with secondary hyperparathyroidism may receive:
Calcimimetics
such as:
Cinacalcet.
These increase sensitivity of the parathyroid calcium-sensing receptor and reduce:
PTH secretion.
59. Diabetes Control
In patients with diabetes, appropriate glycaemic management helps reduce:
Microvascular complications
and contributes to slowing diabetic kidney disease.
However, glycaemic targets should be:
Individualised.
60. Diabetes Medication in CKD
Renal function affects the choice and dosing of:
Glucose-lowering medications.
Some drugs require dose adjustment or avoidance as eGFR declines.
SGLT2 inhibitors have a particularly important role because they provide:
Renal and cardiovascular protection
in suitable patients.
61. Lipid Management
Patients with CKD have high:
Cardiovascular risk.
Therefore lipid management is important.
Many appropriate CKD patients are treated with:
Statin therapy
according to their age, CKD stage and cardiovascular risk.
62. Cardiovascular Risk
Cardiovascular disease is one of the major causes of morbidity and mortality in CKD.
Management therefore includes attention to:
Blood pressure.
Lipids.
Diabetes.
Smoking.
Exercise and physical activity where appropriate.
Weight and overall cardiovascular health.
63. Volume Status Monitoring
The kidneys regulate:
Sodium and water balance.
As kidney function deteriorates, patients may develop:
Fluid retention.
Clinical assessment includes:
Body weight.
Peripheral oedema.
Blood pressure.
Breathlessness.
Signs of pulmonary congestion.
64. Fluid Overload
Fluid overload may cause:
Peripheral oedema.
Pulmonary oedema.
Hypertension.
Heart failure.
Management may involve:
Salt restriction.
Diuretics.
Fluid management.
Dialysis in severe advanced kidney failure.
65. Hyperkalaemia
CKD reduces the ability to excrete:
Potassium.
Severe hyperkalaemia can cause:
Life-threatening cardiac arrhythmias.
Therefore potassium should be monitored, particularly in advanced CKD and patients receiving:
ACE inhibitors.
ARBs.
Mineralocorticoid receptor antagonists.
66. Metabolic Acidosis
Reduced renal acid excretion can produce:
Metabolic acidosis.
Chronic metabolic acidosis may contribute to:
Muscle wasting.
Bone disease.
CKD progression.
Selected patients may require:
Oral bicarbonate therapy.
67. Avoid Nephrotoxic Drugs
An important principle is:
Avoid unnecessary nephrotoxins.
Particularly important drugs include:
NSAIDs.
NSAIDs reduce renal prostaglandin synthesis and may precipitate:
AKI
especially in susceptible CKD patients.
68. Medication Dose Adjustment
Many medications are eliminated by the kidneys.
As GFR declines, some drugs require:
Dose reduction
or
Longer dosing intervals.
Failure to adjust doses can cause:
Drug accumulation and toxicity.
69. Contrast and Other Renal Insults
Potential renal insults should be considered carefully, particularly in patients with advanced CKD.
The key principle is to:
Minimise avoidable additional kidney injury
while still performing clinically necessary investigations and treatments.
70. Smoking
Smoking accelerates:
Cardiovascular disease
and may contribute to:
CKD progression.
Smoking cessation is therefore an important component of CKD management.
71. Vaccination and Infection Prevention
Advanced CKD and dialysis can increase susceptibility to infection.
Appropriate vaccination may include protection against:
Influenza.
Pneumococcal disease.
Hepatitis B, particularly when dialysis is anticipated or used.
Recommendations depend on local guidelines and individual circumstances.
72. Monitoring CKD Progression
Patients with CKD require periodic monitoring of:
Serum creatinine.
eGFR.
Urine ACR.
Blood pressure.
Potassium.
Bicarbonate.
Depending on disease severity, monitoring may also include:
Haemoglobin.
Calcium.
Phosphate.
PTH.
73. Albuminuria Categories
Modern CKD classification does not depend only on GFR.
Albuminuria is also important.
It is commonly divided into:
A1 – normal to mildly increased albuminuria.
A2 – moderately increased albuminuria.
A3 – severely increased albuminuria.
Higher albuminuria generally predicts:
Greater renal and cardiovascular risk.
74. GFR Categories
CKD can also be staged according to GFR:
G1 – normal or high GFR with evidence of kidney disease.
G2 – mildly reduced.
G3a – mild-to-moderately reduced.
G3b – moderately-to-severely reduced.
G4 – severely reduced.
G5 – kidney failure.
75. Why Both GFR and Albuminuria Matter
Two patients with the same eGFR may have very different risks depending on their:
Albuminuria.
Therefore modern CKD assessment combines:
Cause + GFR category + albuminuria category.
This is often called:
CGA classification.
76. Kidney Replacement Therapy
Advanced CKD may eventually require:
Kidney replacement therapy.
The principal options are:
Haemodialysis.
Peritoneal dialysis.
Kidney transplantation.
77. Preparing for Kidney Replacement Therapy
Preparation should begin before an emergency develops.
Depending on the patient, this may include:
Education about treatment options.
Transplant assessment.
Creation of dialysis access.
Planning for peritoneal dialysis.
Conservative kidney management when appropriate.
78. Conservative Kidney Management
Not every patient with advanced CKD chooses or benefits from dialysis.
For selected patients, particularly those with substantial comorbidity or personal preference against dialysis, treatment may focus on:
Symptom control.
Fluid management.
Anaemia management.
Quality of life.
Supportive and palliative care where appropriate.
79. Causes of CKD – Note Form
Diabetes mellitus:
Diabetic kidney disease.
Albuminuria and progressive GFR decline.
Kimmelstiel–Wilson nodules classically.
Chronic glomerular disease:
IgA nephropathy.
FSGS.
Lupus nephritis.
Other chronic glomerulopathies.
Hypertension and vascular disease:
Nephrosclerosis.
Renal ischaemia.
Progressive nephron loss.
Reflux nephropathy:
Childhood vesicoureteric reflux.
Renal scarring.
Hypertension and CKD.
ADPKD:
Inherited cystic kidney disease.
Hypertension.
Progressive CKD.
Chronic obstruction:
Prostatic disease.
Tumours.
Stones.
Neurogenic bladder.
Multiple myeloma:
Light-chain cast nephropathy.
AL amyloidosis.
Monoclonal deposition disease.
Amyloidosis:
Heavy proteinuria.
Nephrotic syndrome.
Progressive CKD.
Chronic tubulointerstitial nephritis:
Tubular atrophy.
Interstitial fibrosis.
Progressive CKD.
Previous severe or recurrent AKI:
Incomplete recovery.
Subsequent CKD.
80. Management of CKD – Note Form
Control blood pressure:
ACE inhibitor or ARB particularly in albuminuric CKD.
Additional antihypertensives as necessary.
Reduce albuminuria:
ACE inhibitor OR ARB.
SGLT2 inhibitor in suitable patients.
Finerenone in selected patients with type 2 diabetes and albuminuric CKD.
Treat anaemia:
Assess ferritin and TSAT.
Replace iron when indicated.
ESA therapy when appropriate.
Manage CKD-MBD:
Control phosphate.
Treat vitamin D abnormalities appropriately.
Control secondary hyperparathyroidism.
Diet:
Avoid excessive sodium.
Restrict potassium only when clinically indicated.
Maintain adequate nutrition and energy intake.
Diabetes:
Individualised glycaemic control.
Use kidney-protective therapy where appropriate.
Cardiovascular risk:
Blood-pressure control.
Lipid management.
Smoking cessation.
Fluid status:
Monitor weight and oedema.
Use diuretics when appropriate.
Prevent further renal injury:
Avoid unnecessary NSAIDs and other nephrotoxins.
Adjust renally cleared medications.
Prevent and promptly treat AKI.
Advanced disease:
Plan transplantation, haemodialysis, peritoneal dialysis or conservative kidney management as appropriate.
81. Important Corrections to the Original Notes
The term:
“Chronic renal failure – CRF”
should generally be replaced by:
CHRONIC KIDNEY DISEASE – CKD.
The percentages given for causes of CRF in the UK are:
Historical figures.
They should not be treated as fixed modern epidemiological percentages.
The universal blood-pressure target:
“<130/75 mmHg”
is outdated as a single target for every patient.
Modern treatment is:
Individualised according to albuminuria, cardiovascular risk, age and tolerance.
The original management focuses on:
ACE inhibitors.
An important modern addition is:
SGLT2 INHIBITORS
which now play a major kidney-protective role in many suitable CKD patients.
The statement:
“Low potassium diet”
should be changed to:
POTASSIUM RESTRICTION WHEN HYPERKALAEMIA OR A SIGNIFICANT RISK OF HYPERKALAEMIA IS PRESENT.
It is not necessary for every CKD patient.
The statement:
“Maintain Hb >10 g/dL”
is an older simplified ESA target.
Modern anaemia management is:
Individualised and does not aim to normalise haemoglobin completely.
The term:
“Post-ARF”
should be replaced by:
CKD FOLLOWING ACUTE KIDNEY INJURY – AKI.
82. CKD Progression – High-Yield Sequence
A useful overall sequence is:
UNDERLYING RENAL DISEASE
↓
NEPHRON LOSS
↓
COMPENSATORY HYPERFILTRATION OF REMAINING NEPHRONS
↓
INTRAGLOMERULAR HYPERTENSION
↓
PROTEINURIA + FURTHER GLOMERULAR DAMAGE
↓
GLOMERULOSCLEROSIS + INTERSTITIAL FIBROSIS
↓
PROGRESSIVE FALL IN GFR
↓
ADVANCED CKD / ESKD
This explains why reducing:
Blood pressure
and
Intraglomerular pressure
can slow progression.
Key Clinical Pattern
Think of CKD as:
KIDNEY ABNORMALITY FOR ≥3 MONTHS.
The major causes to remember are:
DIABETES + HYPERTENSION/VASCULAR DISEASE + GLOMERULAR DISEASE + INHERITED/STRUCTURAL DISEASE + OBSTRUCTION + TUBULOINTERSTITIAL DISEASE.
The major complications are:
FLUID OVERLOAD + HYPERKALAEMIA + METABOLIC ACIDOSIS + ANAEMIA + CKD-MBD + CARDIOVASCULAR DISEASE.
The major management principles are:
CONTROL BP → REDUCE ALBUMINURIA → ACEi/ARB WHEN INDICATED → SGLT2 INHIBITOR WHEN APPROPRIATE → CONTROL DIABETES → TREAT ANAEMIA → MANAGE CKD-MBD → CONTROL FLUID/ELECTROLYTES → AVOID NEPHROTOXINS → REDUCE CARDIOVASCULAR RISK.
And in advanced disease:
PLAN EARLY FOR TRANSPLANTATION, DIALYSIS OR CONSERVATIVE KIDNEY MANAGEMENT.
- Published on
Medicine – Anaemia of Chronic Kidney Disease
Anaemia of chronic kidney disease (CKD) is a common complication of progressive renal impairment. The older term “anaemia of chronic renal failure (CRF)” is now more commonly replaced by anaemia of CKD.
The anaemia develops mainly because diseased kidneys produce insufficient erythropoietin (EPO), although iron deficiency, inflammation, shortened red-cell survival and other factors may also contribute.
1. Relationship to Renal Function
The original note states:
“GFR <35 mL/min.”
Anaemia does become increasingly common as GFR declines, but there is no single GFR threshold at which renal anaemia begins.
It becomes particularly important in:
Moderate-to-advanced CKD, especially CKD stages 4 and 5.
Patients with diabetes may sometimes develop anaemia at a relatively earlier stage of CKD.
2. Normal Erythropoietin Production
Erythropoietin (EPO) is a glycoprotein hormone produced predominantly by specialised interstitial cells in the:
Kidneys.
Its major function is to stimulate:
Red blood cell production in the bone marrow.
3. Normal Response to Hypoxia
When tissue oxygen delivery falls, healthy kidneys detect the reduced oxygen availability and increase:
EPO production.
EPO then acts on erythroid precursor cells in the bone marrow, increasing:
Erythropoiesis.
This raises the circulating red-cell mass and improves oxygen delivery.
4. EPO Deficiency in CKD
In CKD, progressive tubulointerstitial damage reduces the kidney’s ability to produce an appropriate amount of:
Erythropoietin.
Consequently, the bone marrow receives inadequate stimulation for red-cell production.
This is the major mechanism responsible for:
Anaemia of CKD.
5. EPO Is Relatively Deficient
The problem is best described as:
Relative erythropoietin deficiency.
The patient may still have measurable EPO in the blood, but the concentration is inappropriately low for the degree of anaemia.
6. Type of Anaemia
Classically, anaemia of CKD is:
Normocytic
and
Normochromic.
Therefore:
Low haemoglobin + normal MCV + advanced CKD → consider renal anaemia.
However, another abnormality such as iron deficiency can alter this pattern.
7. Additional Causes of Anaemia in CKD
EPO deficiency is central, but CKD-associated anaemia is often:
Multifactorial.
Other contributing factors include:
Iron deficiency.
Chronic inflammation.
Reduced availability of stored iron.
Shortened red-cell survival.
Blood loss.
Nutritional deficiencies.
Dialysis-related blood loss in selected patients.
8. Iron Deficiency
Iron deficiency is particularly important because adequate iron is required for:
Haemoglobin synthesis
and for an effective response to:
Erythropoiesis-stimulating therapy.
Iron deficiency may be:
Absolute
or
Functional.
9. Absolute Iron Deficiency
In absolute iron deficiency, the body’s actual iron stores are depleted.
Possible causes in CKD include:
Chronic blood loss.
Gastrointestinal bleeding.
Repeated blood sampling.
Dialysis-associated losses.
Reduced dietary intake or absorption.
10. Functional Iron Deficiency
In functional iron deficiency, iron stores may be present but iron cannot be mobilised effectively for:
Erythropoiesis.
This occurs particularly in chronic inflammatory states.
An important mediator is:
Hepcidin.
11. Hepcidin
Hepcidin is a major regulator of iron metabolism.
It reduces:
Intestinal iron absorption
and
Release of stored iron from macrophages.
Hepcidin levels can be elevated in CKD because of:
Inflammation
and
Reduced renal clearance.
12. Effect of Increased Hepcidin
Increased hepcidin means iron may remain trapped in storage sites rather than being made available to the bone marrow.
Therefore, a CKD patient may have:
Adequate or elevated ferritin
but still have insufficient iron available for erythropoiesis.
This is why ferritin alone is not sufficient to assess iron status.
13. Shortened Red-Cell Survival
Uraemia can reduce the normal lifespan of circulating:
Red blood cells.
This contributes further to anaemia.
Therefore, CKD anaemia reflects both:
Reduced red-cell production
and
Reduced red-cell survival.
14. Clinical Features
Symptoms depend on the severity and rate of development of the anaemia.
Possible features include:
Fatigue.
Weakness.
Reduced exercise tolerance.
Breathlessness on exertion.
Palpitations.
Dizziness.
Reduced concentration.
15. Cardiovascular Consequences
Severe or prolonged anaemia increases cardiac workload.
It may contribute to:
Tachycardia.
Left ventricular hypertrophy.
Worsening heart failure.
Reduced exercise capacity.
This is particularly important because CKD patients already have a high cardiovascular risk.
16. Investigation
Anaemia in a patient with CKD should not automatically be assumed to result from:
EPO deficiency.
Other causes should be excluded.
Initial assessment commonly includes:
Full blood count.
MCV.
Reticulocyte count where appropriate.
Ferritin.
Transferrin saturation – TSAT.
17. Additional Investigations
Depending on the clinical situation, additional tests may include:
Vitamin B12.
Folate.
Markers of inflammation.
Tests for haemolysis.
Investigation for gastrointestinal or other blood loss.
The purpose is to identify reversible causes before attributing the anaemia entirely to CKD.
18. Ferritin
Serum ferritin provides information about:
Body iron stores.
A low ferritin strongly supports:
Absolute iron deficiency.
However, ferritin is also an:
Acute-phase reactant.
19. Limitation of Ferritin
Because ferritin increases during inflammation, a patient with CKD may have:
Normal or elevated ferritin
despite having insufficient iron available for erythropoiesis.
Therefore ferritin should usually be interpreted together with:
Transferrin saturation – TSAT.
20. Transferrin Saturation
TSAT estimates how much circulating transferrin is carrying iron that can be delivered to tissues.
A low TSAT suggests:
Reduced iron availability.
Therefore:
Ferritin → iron stores.
TSAT → circulating iron availability.
Both are useful in CKD.
21. Management Principles
Treatment aims to:
Correct iron deficiency.
Improve haemoglobin and symptoms.
Use erythropoiesis-stimulating therapy when appropriate.
Avoid unnecessary blood transfusion.
Treat other reversible causes of anaemia.
22. Iron Replacement
Iron deficiency should be corrected before or alongside erythropoiesis-stimulating therapy.
Iron can be administered:
Orally
or
Intravenously.
The best route depends on:
CKD stage.
Dialysis status.
Severity of iron deficiency.
Response to previous oral iron.
Tolerance.
23. Intravenous Iron
The original note states:
“If ferritin <100, give intravenous iron.”
This is too simplified for modern practice.
Decisions about iron therapy are generally based on:
Ferritin + TSAT + haemoglobin + dialysis status + clinical context.
A single ferritin threshold should not be used in isolation.
24. Iron in Haemodialysis
Patients receiving:
Haemodialysis
frequently require intravenous iron because of ongoing iron losses and the difficulty of maintaining sufficient available iron.
Therefore:
IV iron is commonly used in haemodialysis patients.
25. Oral Iron
In patients with CKD who are not receiving haemodialysis, treatment may begin with:
Oral iron
in suitable circumstances.
If oral treatment is:
Ineffective, poorly tolerated, or inadequate,
intravenous iron may be considered.
26. Erythropoiesis-Stimulating Agents
The original notes refer to:
Subcutaneous EPO injections.
The broader modern term is:
Erythropoiesis-stimulating agents – ESAs.
These drugs stimulate the bone marrow to increase:
Red blood cell production.
27. Examples of ESAs
Examples include:
Epoetin alfa.
Epoetin beta.
Darbepoetin alfa.
Different preparations have different durations of action and dosing schedules.
28. Administration of ESAs
ESAs may be administered:
Subcutaneously
or
Intravenously
depending on the agent and clinical setting.
Therefore, ESA therapy is not restricted to:
Subcutaneous injection alone.
29. When ESA Therapy Is Considered
ESA therapy is generally considered when a CKD patient has persistent clinically important anaemia after:
Iron deficiency and other reversible causes have been assessed and treated.
The decision depends on:
Haemoglobin concentration.
Symptoms.
Rate of haemoglobin decline.
Need to avoid transfusion.
Cardiovascular and thrombotic risks.
30. Why Iron Must Be Adequate
ESAs stimulate the bone marrow to make new red cells.
This substantially increases the marrow’s requirement for:
Iron.
If iron availability is inadequate, the patient may show a poor response to ESA treatment.
Therefore:
ESA + inadequate iron → poor erythropoietic response.
31. ESA Treatment Is Not Designed to Normalise Haemoglobin Completely
An important modern principle is that ESA therapy should not routinely attempt to restore haemoglobin to the normal range of a healthy person.
Excessive correction has been associated with increased risk of adverse cardiovascular and thrombotic events.
Therefore, treatment targets are:
Individualised
rather than simply aiming for a completely normal haemoglobin.
32. Adverse Effects of ESA Therapy
Important complications include:
Hypertension.
Thrombotic events.
Vascular-access thrombosis.
Excessive haemoglobin elevation may increase:
Cardiovascular risk.
33. ESA Resistance
If haemoglobin fails to improve adequately despite ESA therapy, consider:
Iron deficiency.
Inflammation or infection.
Ongoing blood loss.
Inadequate dialysis.
Hyperparathyroidism.
Nutritional deficiency.
Haematological disease.
The ESA dose should not simply be increased indefinitely without identifying the reason for poor response.
34. Blood Transfusion
Red-cell transfusion may be necessary in selected patients with:
Severe symptomatic anaemia.
Acute major blood loss.
Haemodynamic instability.
However, repeated transfusions are generally avoided when possible in potential kidney-transplant candidates.
35. Why Transfusions Are Avoided in Transplant Candidates
Blood transfusions can expose the patient to foreign:
HLA antigens.
This may cause:
HLA sensitisation.
Sensitisation can make it more difficult to find a compatible kidney donor and may increase transplant immunological risk.
Therefore:
Avoid unnecessary transfusion in potential renal-transplant candidates.
36. Anaemia of CKD – Pathophysiology Note Form
CKD → renal interstitial damage.
Renal damage → inadequate EPO production.
Low EPO stimulation → reduced bone-marrow erythropoiesis.
CKD → inflammation + increased hepcidin.
Increased hepcidin → reduced intestinal iron absorption + reduced release of stored iron.
Reduced iron availability → impaired haemoglobin synthesis.
Uraemia → shortened RBC survival.
Final result → predominantly normocytic normochromic anaemia.
37. Anaemia of CKD – Investigation Note Form
Full blood count:
Low haemoglobin.
Usually normocytic and normochromic.
Ferritin:
Assesses iron stores.
Low level strongly suggests absolute iron deficiency.
Can be falsely elevated by inflammation.
TSAT:
Assesses available circulating iron.
Should be interpreted with ferritin.
Other tests when indicated:
Vitamin B12.
Folate.
Reticulocytes.
Inflammatory markers.
Haemolysis screen.
Assessment for blood loss.
38. Anaemia of CKD – Treatment Note Form
Step 1:
Confirm anaemia and assess alternative causes.
Step 2:
Assess iron status using:
Ferritin.
TSAT.
Step 3:
Correct iron deficiency.
Oral iron may be appropriate in some non-dialysis patients.
IV iron is commonly used in haemodialysis and when oral therapy is inadequate.
Step 4:
Consider an ESA for persistent significant CKD-related anaemia.
Examples:
Epoetin.
Darbepoetin.
Step 5:
Monitor:
Haemoglobin.
Blood pressure.
Iron status.
Response to therapy.
Step 6:
Avoid unnecessary blood transfusion, particularly in potential transplant recipients.
39. Important Corrections to the Original Notes
The statement:
“GFR <35 mL/min”
should not be treated as an absolute diagnostic threshold.
A better principle is:
ANAEMIA BECOMES MORE COMMON AND MORE SEVERE AS CKD PROGRESSES, PARTICULARLY IN ADVANCED CKD.
The statement:
“Caused by lack of EPO”
is fundamentally correct but incomplete.
CKD anaemia is usually multifactorial:
RELATIVE EPO DEFICIENCY + IRON RESTRICTION + INFLAMMATION + SHORTENED RBC SURVIVAL ± BLOOD LOSS.
The statement:
“Subcutaneous EPO injections”
is better modernised to:
ERYTHROPOIESIS-STIMULATING AGENTS – ESAs, GIVEN SUBCUTANEOUSLY OR INTRAVENOUSLY DEPENDING ON THE CLINICAL SETTING.
The statement:
“Ferritin <100 → IV iron”
is too rigid.
Iron treatment should be guided by:
FERRITIN + TSAT + HAEMOGLOBIN + DIALYSIS STATUS + CLINICAL CONTEXT.
Key Clinical Pattern
Think:
ADVANCED CKD + NORMOCYTIC NORMOCHROMIC ANAEMIA → RELATIVE EPO DEFICIENCY.
The central mechanism is:
↓ RENAL FUNCTION → ↓ APPROPRIATE EPO PRODUCTION → ↓ BONE-MARROW RBC PRODUCTION → ANAEMIA.
But remember the important additional pathway:
CKD/INFLAMMATION → ↑ HEPCIDIN → ↓ AVAILABLE IRON → WORSENING ANAEMIA.
Management can be remembered as:
CHECK IRON → REPLACE IRON WHEN INDICATED → ESA WHEN APPROPRIATE → MONITOR Hb AND BP → AVOID UNNECESSARY TRANSFUSION.
- Published on
Medicine – Renal Osteodystrophy
Renal osteodystrophy refers specifically to the bone abnormalities that develop as a consequence of chronic kidney disease (CKD) and the associated disturbances of calcium, phosphate, vitamin D and parathyroid hormone metabolism.
It forms part of the broader condition called:
CKD–mineral and bone disorder (CKD-MBD).
CKD-MBD includes not only bone disease but also abnormalities of calcium, phosphate, PTH and vitamin D metabolism, together with vascular and soft-tissue calcification.
1. Basic Pathophysiology
As kidney function progressively declines, the kidneys become less able to:
Excrete phosphate.
Activate vitamin D.
Maintain normal calcium and phosphate balance.
These abnormalities stimulate:
Parathyroid hormone – PTH – secretion.
Persistent elevation of PTH produces:
Secondary hyperparathyroidism.
2. Normal Vitamin D Activation
Vitamin D obtained from the skin or diet is first converted in the liver to:
25-hydroxyvitamin D – 25(OH)D.
The kidney then converts this to the biologically active form:
1,25-dihydroxyvitamin D – 1,25(OH)₂D
also called:
Calcitriol.
This renal conversion is performed primarily by:
1α-hydroxylase.
3. Reduced Active Vitamin D in CKD
As functioning renal mass decreases, the ability of the kidney to produce:
Calcitriol
declines.
This is an important component of the mineral disturbance associated with advanced CKD.
4. Role of FGF23
An important modern addition to the traditional explanation is:
Fibroblast growth factor 23 – FGF23.
As phosphate retention begins, FGF23 levels increase.
FGF23 promotes renal phosphate excretion but also:
Suppresses renal calcitriol production.
Therefore, declining calcitriol can occur relatively early in CKD.
5. Effect of Low Calcitriol
Calcitriol normally promotes:
Intestinal calcium absorption.
When calcitriol levels fall, intestinal calcium absorption decreases.
This contributes to:
Hypocalcaemia or a tendency toward lower ionised calcium.
6. Calcium Malabsorption
The original note states:
“Malabsorption of calcium.”
More precisely, CKD causes:
Reduced intestinal calcium absorption
largely because of reduced active vitamin D activity.
This contributes to stimulation of the parathyroid glands.
7. Phosphate Retention
Normal kidneys excrete excess phosphate.
As GFR falls, phosphate excretion becomes progressively impaired.
This leads eventually to:
Phosphate retention
and, particularly in advanced CKD:
Hyperphosphataemia.
8. Hyperphosphataemia and Calcium
Increased phosphate contributes to disturbances in calcium balance and directly stimulates mechanisms promoting:
Secondary hyperparathyroidism.
Therefore, phosphate retention is a central component of CKD-MBD.
9. Secondary Hyperparathyroidism
The parathyroid glands respond to CKD-related biochemical disturbances by increasing:
PTH secretion.
This is called:
Secondary hyperparathyroidism.
The parathyroid glands are responding appropriately to an abnormal physiological environment rather than functioning autonomously initially.
10. Causes of Increased PTH in CKD
Important stimuli include:
Reduced ionised calcium.
Phosphate retention and hyperphosphataemia.
Reduced calcitriol.
Reduced activation of the calcium-sensing receptor and vitamin D receptor pathways.
With persistent stimulation, the parathyroid glands undergo:
Hyperplasia.
11. Role of Acidosis
The original notes also list:
Acidosis.
Chronic metabolic acidosis can contribute to:
Bone mineral loss
and
Abnormal bone metabolism.
However, the principal drivers of secondary hyperparathyroidism are the disturbances involving:
Phosphate, calcium, calcitriol and parathyroid regulation.
12. PTH and Bone
Persistently elevated PTH increases:
Bone turnover.
Bone resorption and remodelling become excessive.
The classical high-turnover bone lesion associated with severe secondary hyperparathyroidism is:
Osteitis fibrosa.
13. Osteitis Fibrosa
Osteitis fibrosa results from prolonged excessive PTH activity.
There is:
Increased osteoclastic bone resorption.
Increased bone turnover.
Replacement of some bone by fibrous tissue.
Severe disease may produce characteristic skeletal abnormalities.
14. Brown Tumours
Severe hyperparathyroidism can occasionally produce:
Brown tumours.
These are not true neoplasms.
They represent focal areas of:
Bone resorption, fibrosis, haemorrhage and giant-cell accumulation.
They are now uncommon with appropriate CKD management.
15. Osteomalacia
Another possible component of renal osteodystrophy is:
Osteomalacia.
Osteomalacia means:
Defective mineralisation of newly formed bone matrix.
Historically, aluminium toxicity in dialysis patients was an important cause, although this is much less common with modern dialysis practice.
16. Adynamic Bone Disease
An important modern category not included in the original notes is:
Adynamic bone disease.
This is a:
Low-turnover bone disorder
in which bone formation and resorption are both reduced.
It can occur when PTH activity is excessively suppressed, particularly in some patients receiving dialysis.
17. Why Excessive PTH Suppression Can Be Harmful
PTH should not simply be reduced as much as possible.
Excessive suppression can contribute to:
Adynamic bone disease.
Therefore, CKD-MBD treatment aims for appropriate control of mineral metabolism rather than complete elimination of PTH secretion.
18. Osteoporosis
Patients with CKD can also develop:
Osteoporosis
with reduced bone strength and increased fracture risk.
However, osteoporosis and renal osteodystrophy are not exactly synonymous.
A patient with CKD may have both:
CKD-related abnormalities of bone turnover/mineralisation
and
Osteoporosis.
19. Major Patterns of Renal Osteodystrophy
Renal osteodystrophy can therefore include different patterns:
High-turnover bone disease due to secondary hyperparathyroidism.
Osteomalacia due to defective mineralisation.
Adynamic low-turnover bone disease.
Mixed uraemic osteodystrophy.
These patterns are more precise than simply describing all renal bone disease as osteoporosis.
20. Clinical Features
Many patients initially have:
No obvious skeletal symptoms.
More advanced disease can cause:
Bone pain.
Muscle weakness.
Skeletal deformity.
Fragility fractures.
Growth abnormalities in children.
21. Fractures
Abnormal bone turnover and mineralisation increase the risk of:
Fragility fractures.
Fracture risk may be further increased by:
Older age.
Corticosteroid exposure.
Reduced physical activity.
Malnutrition.
Coexisting osteoporosis.
22. Osteosclerosis
Renal osteodystrophy can sometimes produce areas of:
Osteosclerosis.
A classic radiological example is:
Rugger-jersey spine.
23. Rugger-Jersey Spine
The rugger-jersey spine describes bands of increased bone density along the superior and inferior vertebral endplates.
The vertebral body develops alternating:
Dense
and
Less dense
areas.
The appearance resembles the horizontal stripes of a rugby jersey.
24. Other Radiological Features
Severe secondary hyperparathyroidism may produce:
Subperiosteal bone resorption.
This is particularly characteristic along the:
Radial aspects of the middle phalanges.
Other abnormalities can include:
Bone cyst-like lesions.
Osteosclerosis.
Fractures.
25. Skull Changes
Severe hyperparathyroid bone disease can produce a:
“Salt-and-pepper” skull appearance.
This results from diffuse abnormalities of skull mineralisation.
26. Laboratory Assessment
Evaluation of CKD-MBD commonly includes measurement of:
Serum calcium.
Serum phosphate.
PTH.
Alkaline phosphatase.
25-hydroxyvitamin D.
These values should be interpreted together rather than relying on a single measurement.
27. Typical Biochemical Pattern
In advanced untreated CKD with secondary hyperparathyroidism, a typical pattern may include:
Raised phosphate.
Normal or low calcium.
Raised PTH.
Reduced calcitriol.
Raised alkaline phosphatase when bone turnover is high.
However, the biochemical pattern varies with CKD stage and treatment.
28. Treatment Principles
Management of renal osteodystrophy is part of the broader treatment of:
CKD-MBD.
The major goals are to control:
Phosphate balance.
Calcium balance.
Vitamin D abnormalities.
Secondary hyperparathyroidism.
Metabolic acidosis where present.
29. Dietary Phosphate Control
The first step in controlling phosphate may include:
Dietary phosphate restriction or modification.
Particular attention may be given to highly absorbable phosphate from:
Processed foods containing phosphate additives.
Management should avoid unnecessary nutritional restriction.
30. Phosphate Binders
If phosphate remains elevated, patients may require:
Phosphate binders.
These drugs bind dietary phosphate in the gastrointestinal tract and reduce its:
Intestinal absorption.
They are generally taken:
With meals.
31. Calcium-Based Phosphate Binders
An example is:
Calcium acetate.
Another is:
Calcium carbonate.
These reduce phosphate absorption but also provide calcium.
32. Limitations of Calcium-Based Binders
Excessive calcium exposure can contribute to:
Hypercalcaemia
and potentially:
Vascular and soft-tissue calcification.
Therefore, non-calcium-containing phosphate binders may be preferred in selected patients.
33. Non-Calcium Phosphate Binders
Examples include:
Sevelamer
and
Lanthanum carbonate.
These lower phosphate without adding a substantial calcium load.
The appropriate binder depends on the individual patient’s biochemical profile.
34. Vitamin D Treatment
The original notes mention:
1-alfacalcidol.
The correct drug name is:
Alfacalcidol.
Alfacalcidol is a vitamin D analogue that can be converted by the liver to an active vitamin D compound without requiring normal renal 1α-hydroxylation.
35. Active Vitamin D Therapy
Agents used in selected CKD patients include:
Calcitriol
and
Vitamin D analogues such as alfacalcidol.
These can suppress:
Excessive PTH secretion.
However, they must be used carefully because they can increase:
Calcium
and
phosphate.
36. Nutritional Vitamin D
Patients may also have ordinary vitamin D deficiency.
Therefore:
25-hydroxyvitamin D deficiency
may require treatment with nutritional vitamin D according to the clinical situation.
This should be distinguished from the impaired renal production of:
Calcitriol.
37. Calcimimetics
An important modern treatment not included in the original notes is:
Calcimimetic therapy.
An important example is:
Cinacalcet.
Calcimimetics increase the sensitivity of the parathyroid:
Calcium-sensing receptor.
This suppresses:
PTH secretion.
38. Cinacalcet
Cinacalcet is particularly useful for controlling:
Secondary hyperparathyroidism in selected dialysis patients.
An important adverse effect is:
Hypocalcaemia.
Therefore calcium must be monitored.
39. Correction of Metabolic Acidosis
Persistent metabolic acidosis can adversely affect:
Bone metabolism
and
Muscle function.
Appropriate correction of chronic metabolic acidosis may therefore form part of overall CKD management.
40. Parathyroidectomy
If severe secondary hyperparathyroidism remains uncontrolled despite appropriate medical therapy, treatment may require:
Parathyroidectomy.
This is generally reserved for:
Severe, persistent or refractory hyperparathyroidism.
41. Tertiary Hyperparathyroidism
After prolonged secondary hyperparathyroidism, the enlarged parathyroid glands may eventually begin secreting PTH relatively autonomously.
This is called:
Tertiary hyperparathyroidism.
42. Secondary versus Tertiary Hyperparathyroidism
Secondary hyperparathyroidism:
PTH rises appropriately in response to CKD-related disturbances.
Calcium is often normal or low.
Tertiary hyperparathyroidism:
Long-standing parathyroid hyperplasia becomes relatively autonomous.
PTH remains markedly elevated.
Hypercalcaemia may develop.
This can occur in patients with longstanding advanced CKD, including some patients after successful kidney transplantation.
43. Parathyroidectomy in Severe Disease
Surgery may be considered when severe hyperparathyroidism causes persistent:
Very high PTH.
Hypercalcaemia or hyperphosphataemia.
Bone disease.
Other complications
despite appropriate medical treatment.
44. Vascular Calcification
CKD-MBD does not affect only the skeleton.
Disturbances of calcium and phosphate metabolism can contribute to:
Vascular calcification.
This is one reason excessive phosphate and calcium exposure are clinically important.
45. Soft-Tissue Calcification
Calcium-phosphate deposition may also occur in:
Soft tissues.
In severe cases, abnormalities of mineral metabolism can contribute to serious complications such as:
Calciphylaxis,
particularly in patients with advanced CKD.
46. Renal Osteodystrophy – Pathophysiology Note Form
CKD → reduced phosphate excretion.
Phosphate retention → increased FGF23 and eventually hyperphosphataemia.
CKD + increased FGF23 → reduced calcitriol.
Reduced calcitriol → reduced intestinal calcium absorption.
Lower calcium + phosphate abnormalities + reduced calcitriol → increased PTH.
Persistent increased PTH → secondary hyperparathyroidism.
Secondary hyperparathyroidism → increased bone turnover and osteitis fibrosa.
47. Renal Osteodystrophy – Bone Changes Note Form
High-turnover disease:
Secondary hyperparathyroidism.
Osteitis fibrosa.
Subperiosteal bone resorption.
Defective mineralisation:
Osteomalacia.
Low-turnover disease:
Adynamic bone disease.
Osteosclerosis:
Rugger-jersey spine.
Other skeletal manifestations:
Bone pain.
Weakness.
Fragility fractures.
Skeletal deformity.
48. Renal Osteodystrophy – Treatment Note Form
Control phosphate:
Dietary measures.
Phosphate binders.
Calcium acetate or calcium carbonate in selected patients.
Sevelamer or lanthanum as non-calcium alternatives.
Correct vitamin D abnormalities:
Treat nutritional vitamin D deficiency when appropriate.
Active vitamin D or analogues such as calcitriol or alfacalcidol in selected patients.
Control excessive PTH:
Vitamin D receptor activation when appropriate.
Calcimimetics such as cinacalcet in selected dialysis patients.
Treat refractory severe hyperparathyroidism:
Parathyroidectomy.
Correct associated abnormalities:
Metabolic acidosis.
Calcium disturbances.
Other CKD-related metabolic problems.
49. Important Corrections to the Original Notes
The original definition:
“Bone disease resulting from metabolic disturbance in renal failure”
is broadly correct, but modern terminology distinguishes:
RENAL OSTEODYSTROPHY = THE BONE COMPONENT
from:
CKD-MBD = THE BROADER SYSTEMIC MINERAL AND BONE DISORDER.
The statement:
“Low ionised calcium is caused by lack of 1,25-dihydroxyvitamin D”
is broadly correct but incomplete.
Modern understanding also emphasises:
FGF23 elevation
and
phosphate retention.
The term:
“Malabsorption of calcium”
is better expressed as:
REDUCED INTESTINAL CALCIUM ABSORPTION DUE TO REDUCED ACTIVE VITAMIN D ACTIVITY.
The original treatment:
“Vitamin D – 1-alfacalcidol”
should be corrected to:
ALFACALCIDOL
and active vitamin D therapy should be used selectively because excessive treatment may cause:
Hypercalcaemia, hyperphosphataemia and excessive PTH suppression.
The original treatment list should also include the important modern option:
CALCIMIMETICS, SUCH AS CINACALCET,
for selected patients with secondary hyperparathyroidism.
Key Clinical Pattern
The central pathway is:
CKD → PHOSPHATE RETENTION + ↓ CALCITRIOL → ↓ CALCIUM SIGNAL → ↑ PTH → SECONDARY HYPERPARATHYROIDISM → ABNORMAL BONE TURNOVER.
Remember the classic findings:
↑ PHOSPHATE
↓/NORMAL CALCIUM
↓ CALCITRIOL
↑ PTH
± ↑ ALKALINE PHOSPHATASE
The classic skeletal association is:
SECONDARY HYPERPARATHYROIDISM → OSTEOITIS FIBROSA.
The classic radiological sign is:
RUGGER-JERSEY SPINE.
And the major treatment principles are:
CONTROL PHOSPHATE + MANAGE VITAMIN D + CONTROL PTH + PARATHYROIDECTOMY IF SEVERE AND REFRACTORY.
1. Basic Pathophysiology As kidney function progressively declines, the kidneys become less able to: Excrete phosphate. Activate vitamin D. Maintain normal calcium and phosphate balance. These abnormalities stimulate: Parathyroid hormone – PTH – secretion. Persistent elevation of PTH produces: Secondary hyperparathyroidism.
2. Normal Vitamin D Activation Vitamin D obtained from the skin or diet is first converted in the liver to: 25-hydroxyvitamin D – 25(OH)D. The kidney then converts this to the biologically active form: 1,25-dihydroxyvitamin D – 1,25(OH)₂D also called: Calcitriol. This renal conversion is performed primarily by: 1α-hydroxylase.
3. Reduced Active Vitamin D in CKD As functioning renal mass decreases, the ability of the kidney to produce: Calcitriol declines. This is an important component of the mineral disturbance associated with advanced CKD.
4. Role of FGF23 An important modern addition to the traditional explanation is: Fibroblast growth factor 23 – FGF23. As phosphate retention begins, FGF23 levels increase. FGF23 promotes renal phosphate excretion but also: Suppresses renal calcitriol production. Therefore, declining calcitriol can occur relatively early in CKD.
5. Effect of Low Calcitriol Calcitriol normally promotes: Intestinal calcium absorption. When calcitriol levels fall, intestinal calcium absorption decreases. This contributes to: Hypocalcaemia or a tendency toward lower ionised calcium.
6. Calcium Malabsorption The original note states: “Malabsorption of calcium.” More precisely, CKD causes: Reduced intestinal calcium absorption largely because of reduced active vitamin D activity. This contributes to stimulation of the parathyroid glands.
7. Phosphate Retention Normal kidneys excrete excess phosphate. As GFR falls, phosphate excretion becomes progressively impaired. This leads eventually to: Phosphate retention and, particularly in advanced CKD: Hyperphosphataemia.
8. Hyperphosphataemia and Calcium Increased phosphate contributes to disturbances in calcium balance and directly stimulates mechanisms promoting: Secondary hyperparathyroidism. Therefore, phosphate retention is a central component of CKD-MBD.
9. Secondary Hyperparathyroidism The parathyroid glands respond to CKD-related biochemical disturbances by increasing: PTH secretion. This is called: Secondary hyperparathyroidism. The parathyroid glands are responding appropriately to an abnormal physiological environment rather than functioning autonomously initially.
10. Causes of Increased PTH in CKD Important stimuli include: Reduced ionised calcium. Phosphate retention and hyperphosphataemia. Reduced calcitriol. Reduced activation of the calcium-sensing receptor and vitamin D receptor pathways. With persistent stimulation, the parathyroid glands undergo: Hyperplasia.
11. Role of Acidosis The original notes also list: Acidosis. Chronic metabolic acidosis can contribute to: Bone mineral loss and Abnormal bone metabolism. However, the principal drivers of secondary hyperparathyroidism are the disturbances involving: Phosphate, calcium, calcitriol and parathyroid regulation.
12. PTH and Bone Persistently elevated PTH increases: Bone turnover. Bone resorption and remodelling become excessive. The classical high-turnover bone lesion associated with severe secondary hyperparathyroidism is: Osteitis fibrosa.
13. Osteitis Fibrosa Osteitis fibrosa results from prolonged excessive PTH activity. There is: Increased osteoclastic bone resorption. Increased bone turnover. Replacement of some bone by fibrous tissue. Severe disease may produce characteristic skeletal abnormalities.
14. Brown Tumours Severe hyperparathyroidism can occasionally produce: Brown tumours. These are not true neoplasms. They represent focal areas of: Bone resorption, fibrosis, haemorrhage and giant-cell accumulation. They are now uncommon with appropriate CKD management.
15. Osteomalacia Another possible component of renal osteodystrophy is: Osteomalacia. Osteomalacia means: Defective mineralisation of newly formed bone matrix. Historically, aluminium toxicity in dialysis patients was an important cause, although this is much less common with modern dialysis practice.
16. Adynamic Bone Disease An important modern category not included in the original notes is: Adynamic bone disease. This is a: Low-turnover bone disorder in which bone formation and resorption are both reduced. It can occur when PTH activity is excessively suppressed, particularly in some patients receiving dialysis.
17. Why Excessive PTH Suppression Can Be Harmful PTH should not simply be reduced as much as possible. Excessive suppression can contribute to: Adynamic bone disease. Therefore, CKD-MBD treatment aims for appropriate control of mineral metabolism rather than complete elimination of PTH secretion.
18. Osteoporosis Patients with CKD can also develop: Osteoporosis with reduced bone strength and increased fracture risk. However, osteoporosis and renal osteodystrophy are not exactly synonymous. A patient with CKD may have both: CKD-related abnormalities of bone turnover/mineralisation and Osteoporosis.
19. Major Patterns of Renal Osteodystrophy Renal osteodystrophy can therefore include different patterns: High-turnover bone disease due to secondary hyperparathyroidism. Osteomalacia due to defective mineralisation. Adynamic low-turnover bone disease. Mixed uraemic osteodystrophy. These patterns are more precise than simply describing all renal bone disease as osteoporosis.
20. Clinical Features Many patients initially have: No obvious skeletal symptoms. More advanced disease can cause: Bone pain. Muscle weakness. Skeletal deformity. Fragility fractures. Growth abnormalities in children.
21. Fractures Abnormal bone turnover and mineralisation increase the risk of: Fragility fractures. Fracture risk may be further increased by: Older age. Corticosteroid exposure. Reduced physical activity. Malnutrition. Coexisting osteoporosis.
22. Osteosclerosis Renal osteodystrophy can sometimes produce areas of: Osteosclerosis. A classic radiological example is: Rugger-jersey spine.
23. Rugger-Jersey Spine The rugger-jersey spine describes bands of increased bone density along the superior and inferior vertebral endplates. The vertebral body develops alternating: Dense and Less dense areas. The appearance resembles the horizontal stripes of a rugby jersey.
24. Other Radiological Features Severe secondary hyperparathyroidism may produce: Subperiosteal bone resorption. This is particularly characteristic along the: Radial aspects of the middle phalanges. Other abnormalities can include: Bone cyst-like lesions. Osteosclerosis. Fractures.
25. Skull Changes Severe hyperparathyroid bone disease can produce a: “Salt-and-pepper” skull appearance. This results from diffuse abnormalities of skull mineralisation.
26. Laboratory Assessment Evaluation of CKD-MBD commonly includes measurement of: Serum calcium. Serum phosphate. PTH. Alkaline phosphatase. 25-hydroxyvitamin D. These values should be interpreted together rather than relying on a single measurement.
27. Typical Biochemical Pattern In advanced untreated CKD with secondary hyperparathyroidism, a typical pattern may include: Raised phosphate. Normal or low calcium. Raised PTH. Reduced calcitriol. Raised alkaline phosphatase when bone turnover is high. However, the biochemical pattern varies with CKD stage and treatment.
28. Treatment Principles Management of renal osteodystrophy is part of the broader treatment of: CKD-MBD. The major goals are to control: Phosphate balance. Calcium balance. Vitamin D abnormalities. Secondary hyperparathyroidism. Metabolic acidosis where present.
29. Dietary Phosphate Control The first step in controlling phosphate may include: Dietary phosphate restriction or modification. Particular attention may be given to highly absorbable phosphate from: Processed foods containing phosphate additives. Management should avoid unnecessary nutritional restriction.
30. Phosphate Binders If phosphate remains elevated, patients may require: Phosphate binders. These drugs bind dietary phosphate in the gastrointestinal tract and reduce its: Intestinal absorption. They are generally taken: With meals.
31. Calcium-Based Phosphate Binders An example is: Calcium acetate. Another is: Calcium carbonate. These reduce phosphate absorption but also provide calcium.
32. Limitations of Calcium-Based Binders Excessive calcium exposure can contribute to: Hypercalcaemia and potentially: Vascular and soft-tissue calcification. Therefore, non-calcium-containing phosphate binders may be preferred in selected patients.
33. Non-Calcium Phosphate Binders Examples include: Sevelamer and Lanthanum carbonate. These lower phosphate without adding a substantial calcium load. The appropriate binder depends on the individual patient’s biochemical profile.
34. Vitamin D Treatment The original notes mention: 1-alfacalcidol. The correct drug name is: Alfacalcidol. Alfacalcidol is a vitamin D analogue that can be converted by the liver to an active vitamin D compound without requiring normal renal 1α-hydroxylation.
35. Active Vitamin D Therapy Agents used in selected CKD patients include: Calcitriol and Vitamin D analogues such as alfacalcidol. These can suppress: Excessive PTH secretion. However, they must be used carefully because they can increase: Calcium and phosphate.
36. Nutritional Vitamin D Patients may also have ordinary vitamin D deficiency. Therefore: 25-hydroxyvitamin D deficiency may require treatment with nutritional vitamin D according to the clinical situation. This should be distinguished from the impaired renal production of: Calcitriol.
37. Calcimimetics An important modern treatment not included in the original notes is: Calcimimetic therapy. An important example is: Cinacalcet. Calcimimetics increase the sensitivity of the parathyroid: Calcium-sensing receptor. This suppresses: PTH secretion.
38. Cinacalcet Cinacalcet is particularly useful for controlling: Secondary hyperparathyroidism in selected dialysis patients. An important adverse effect is: Hypocalcaemia. Therefore calcium must be monitored.
39. Correction of Metabolic Acidosis Persistent metabolic acidosis can adversely affect: Bone metabolism and Muscle function. Appropriate correction of chronic metabolic acidosis may therefore form part of overall CKD management.
40. Parathyroidectomy If severe secondary hyperparathyroidism remains uncontrolled despite appropriate medical therapy, treatment may require: Parathyroidectomy. This is generally reserved for: Severe, persistent or refractory hyperparathyroidism.
41. Tertiary Hyperparathyroidism After prolonged secondary hyperparathyroidism, the enlarged parathyroid glands may eventually begin secreting PTH relatively autonomously. This is called: Tertiary hyperparathyroidism.
42. Secondary versus Tertiary Hyperparathyroidism Secondary hyperparathyroidism: PTH rises appropriately in response to CKD-related disturbances. Calcium is often normal or low.
Tertiary hyperparathyroidism: Long-standing parathyroid hyperplasia becomes relatively autonomous. PTH remains markedly elevated. Hypercalcaemia may develop. This can occur in patients with longstanding advanced CKD, including some patients after successful kidney transplantation.
43. Parathyroidectomy in Severe Disease Surgery may be considered when severe hyperparathyroidism causes persistent: Very high PTH. Hypercalcaemia or hyperphosphataemia. Bone disease. Other complications despite appropriate medical treatment.
44. Vascular Calcification CKD-MBD does not affect only the skeleton. Disturbances of calcium and phosphate metabolism can contribute to: Vascular calcification. This is one reason excessive phosphate and calcium exposure are clinically important.
45. Soft-Tissue Calcification Calcium-phosphate deposition may also occur in: Soft tissues. In severe cases, abnormalities of mineral metabolism can contribute to serious complications such as: Calciphylaxis, particularly in patients with advanced CKD.
46. Renal Osteodystrophy – Pathophysiology Note Form CKD → reduced phosphate excretion.
Phosphate retention → increased FGF23 and eventually hyperphosphataemia.
CKD + increased FGF23 → reduced calcitriol.
Reduced calcitriol → reduced intestinal calcium absorption.
Lower calcium + phosphate abnormalities + reduced calcitriol → increased PTH.
Persistent increased PTH → secondary hyperparathyroidism.
Secondary hyperparathyroidism → increased bone turnover and osteitis fibrosa.
47. Renal Osteodystrophy – Bone Changes Note Form High-turnover disease: Secondary hyperparathyroidism. Osteitis fibrosa. Subperiosteal bone resorption.
Defective mineralisation: Osteomalacia.
Low-turnover disease: Adynamic bone disease.
Osteosclerosis: Rugger-jersey spine.
Other skeletal manifestations: Bone pain. Weakness. Fragility fractures. Skeletal deformity.
48. Renal Osteodystrophy – Treatment Note Form Control phosphate: Dietary measures. Phosphate binders. Calcium acetate or calcium carbonate in selected patients. Sevelamer or lanthanum as non-calcium alternatives.
Correct vitamin D abnormalities: Treat nutritional vitamin D deficiency when appropriate. Active vitamin D or analogues such as calcitriol or alfacalcidol in selected patients.
Control excessive PTH: Vitamin D receptor activation when appropriate. Calcimimetics such as cinacalcet in selected dialysis patients.
Treat refractory severe hyperparathyroidism: Parathyroidectomy.
Correct associated abnormalities: Metabolic acidosis. Calcium disturbances. Other CKD-related metabolic problems.
49. Important Corrections to the Original Notes The original definition: “Bone disease resulting from metabolic disturbance in renal failure” is broadly correct, but modern terminology distinguishes: RENAL OSTEODYSTROPHY = THE BONE COMPONENT from: CKD-MBD = THE BROADER SYSTEMIC MINERAL AND BONE DISORDER.
The statement: “Low ionised calcium is caused by lack of 1,25-dihydroxyvitamin D” is broadly correct but incomplete. Modern understanding also emphasises: FGF23 elevation and phosphate retention.
The term: “Malabsorption of calcium” is better expressed as: REDUCED INTESTINAL CALCIUM ABSORPTION DUE TO REDUCED ACTIVE VITAMIN D ACTIVITY.
The original treatment: “Vitamin D – 1-alfacalcidol” should be corrected to: ALFACALCIDOL and active vitamin D therapy should be used selectively because excessive treatment may cause: Hypercalcaemia, hyperphosphataemia and excessive PTH suppression.
The original treatment list should also include the important modern option: CALCIMIMETICS, SUCH AS CINACALCET, for selected patients with secondary hyperparathyroidism.
Key Clinical Pattern The central pathway is: CKD → PHOSPHATE RETENTION + ↓ CALCITRIOL → ↓ CALCIUM SIGNAL → ↑ PTH → SECONDARY HYPERPARATHYROIDISM → ABNORMAL BONE TURNOVER. Remember the classic findings: ↑ PHOSPHATE ↓/NORMAL CALCIUM ↓ CALCITRIOL ↑ PTH ± ↑ ALKALINE PHOSPHATASE
The classic skeletal association is: SECONDARY HYPERPARATHYROIDISM → OSTEOITIS FIBROSA. The classic radiological sign is: RUGGER-JERSEY SPINE. And the major treatment principles are: CONTROL PHOSPHATE + MANAGE VITAMIN D + CONTROL PTH + PARATHYROIDECTOMY IF SEVERE AND REFRACTORY.
